

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

The use and impact of social prescribing: A mixed methods feasibility study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037681
Article Type:	Protocol
Date Submitted by the Author:	12-Feb-2020
Complete List of Authors:	Jani, Anant; University of Oxford Medical Sciences Division, Nuffield Department of Primary Care Health Sciences Liyanage, Harshana; University of Oxford Medical Sciences Division, Nuffield Department of Primary Care Health Sciences Hoang, Uy; University of Oxford Medical Sciences Division, Nuffield Department of Primary Care Health Sciences Moore, Lucy; University of Oxford Medical Sciences Division, Nuffield Department of Primary Care Health Sciences Ferreira , Filipa; University of Oxford Medical Sciences Division, Nuffield Department of Primary Care Health Sciences Yonova , Ivelina; Royal College of General Practitioners, Research and Surveillance Centre Tzortziou Brown, Victoria ; Royal College of General Practitioners de Lusignan, Simon; University of Oxford, Nuffield Department of Primary Care Health Sciences; University of Surrey, Department of Clinical and Experimental Medicine
Keywords:	GENERAL MEDICINE (see Internal Medicine), Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PREVENTIVE MEDICINE, PRIMARY CARE, SOCIAL MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

The use and impact of social prescribing: A mixed methods feasibility study protocol

Anant Jani^{1*}, Harshana Liyanage¹, Uy Hoang¹, Lucy Moore¹, Filipa Ferriera¹, Ivelina Ivanova¹,
², Victoria Tzortziou Brown³, Simon de Lusignan^{1,2}

1. University of Oxford, Department of Primary Care Radcliffe Primary Care Building, Radcliffe Observatory Quarter, Woodstock Rd, Oxford, Oxfordshire, UK OX2 6GG
2. University of Surrey, Department of Clinical and Experimental Medicine, Guildford, Surrey, UK GU2 7XH
3. Royal College of General Practitioners, London, UK

*Correspondences should be addressed to simon.delusignan@phc.ox.ac.uk

Word count: 3412

Keywords: social prescribing, health informatics, primary care, social determinants of health

Abstract

Introduction

Approximately 70% of health outcomes are due to social factors. Social prescribing aims to address social factors related to health but the evidence base behind it is limited partly due to a lack of data linking social prescribing activity and outcomes. This mixed methods feasibility study aims to explore approaches to measure and influence the uptake and impact of social prescribing.

Methods and analysis

The quantitative component of the study aims to: identify the characteristics of individuals who receive social prescriptions and describe the use and estimate the impact of social prescribing. We will utilise the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) primary care sentinel network, which covers a population of over 4,000,000 patients. Data will be extracted for five years up to 31 January 2020 based on social prescribing codes recommended by NHS England national guidance and through a social prescribing taxonomy/ontology underpinned by concepts associated with health-related social factors.

The qualitative component aims to explore approaches to understand the contextual factors that will have influenced our quantitative findings with the goal of helping us identify mechanisms to encourage adoption of social prescribing in primary care while improving data quality. It will comprise up to three 90-120 minute focus groups for six to eight participants. The focus group outputs will be analysed using framework analysis and statements derived from the focus groups will be used to create a survey that surveyees can agree or disagree with.

Ethics and dissemination

1
2
3 All RCGP RSC data are pseudonymised at the point of data extraction. No personally identifiable data
4
5 are required for this investigation. This protocol follows the Good Reporting of a Mixed Methods
6
7 Study (GRAMMS) checklist. The study results will be published in a peer-reviewed journal and the
8
9 dataset will be available to other researchers.
10
11
12
13
14
15
16
17
18

19 **Summary: Strengths and limitations of this study**

- 20
21
22
23 - A key strength of this study is that it uses an established and nationally representative
24
25 sentinel network, The Royal College of General Practitioners Research Surveillance Centre
26
27 (RCGP-RSC), which provides access to a large sample of real world evidence (RWE) data that
28
29 has a high-level of data completeness.
30
31
- 32
33 - The practical and feasible approaches identified through our project could be adopted by
34
35 NHS Digital and rolled out nationally across England, yielding information to improve our
36
37 understanding of the current use and impact of social prescribing and also help to elucidate
38
39 best practice for social prescribing.
40
41
- 42
43 - A limitation is that though nationally representative, because GP practices participate on a
44
45 voluntary basis, there is slight underrepresentation of practices with more deprived
46
47 patients, which means there may be some selection bias.
48
49
- 50
51 - Another limitation is that the identification of patient output and outcome metrics will be
52
53 restricted by primary care clinical codes (i.e. Read, CTV3), which do not always align directly
54
55 with the output and outcome metrics of interest.
56
57
58
59
60

Introduction

It is well established that social factors account for around 70% of health outcomes¹:

“Societies that enable all citizens to play a full and useful role in the social, economic and cultural life of their society will be healthier than those where people face insecurity, exclusion and deprivation.”²

Since the 19th century there have been initiatives such as social medicine³ and community health⁴ designed to address social factors related to health at individual and community levels. There are subtle differences between these initiatives but they all largely focus on needs that remain unaddressed in traditional biomedical models.

Social prescribing is a more recent initiative that has been developed to address social factors related to health. Social prescriptions have been used for several years across European countries as “a way of linking patients in primary care with sources of support within the community to help improve their health and well-being.”⁵ Social prescriptions are varied and include activities focused on health, education, skills development, sports and leisure/art activities.⁶ If utilised well, they can help to deliver several benefits to individuals and health and care systems including⁷: giving a route for health and care systems to address social factors related to health; promoting self-care; support job creation by funnelling resources to local Voluntary, Community and Social Enterprise (VCSE) organisations; building stronger communities; reducing service utilisation including GP appointments, secondary care referrals and accident and emergency attendances.

A wide variety of approaches are included within the umbrella of social prescriptions. A recent systematic review⁵ indicated that while there have been 15 studies into the effects of social

1
2
3 prescriptions, none were of sufficient quality to allow a strong recommendation for their use. More
4
5 robust evidence is required to strategically inform the development of social prescriptions and to
6
7 establish social prescriptions as an evidence-based intervention that clinicians feel comfortable in
8
9 regularly using.
10

11
12
13 A major barrier to the generation of evidence that could facilitate evaluation of social prescribing is
14
15 the lack of data on what social prescribing activity is taking place and the outcomes delivered for
16
17 people taking up social prescribing. This stems from the lack of standardisation of recording, a
18
19 limited list of formal codes associated with social prescribing as well as likely variation in the uptake,
20
21 use and quality of data recorded by clinicians.
22
23

24
25 English general practice is an ideal location to assess the feasibility of measuring the uptake and
26
27 impact of social prescribing. English general practices have a registration-based system (one patient
28
29 registered with a single practice) and are highly computerised.⁸ Computerised medical record (CMR)
30
31 systems have been widely used for measuring quality and outcomes in general practice. Where data
32
33 are likely to be complex, as we anticipate in this study, ontologies provide a formal method to
34
35 specify how we will measure the uptake and impact of social prescribing.^{9,10}
36
37
38
39

40
41 We can readily access a nationally representative sample of data through the Royal College of
42
43 General Practitioners Research Surveillance Centre (RCGP-RSC) sentinel network, a network of over
44
45 500 general practices.^{11, 12} Finally, England is also an ideal location for this study because there is a
46
47 strong national push to promote social prescribing as a mechanism to improve patient and
48
49 population outcomes while optimising resource utilisation (Box 1).
50
51
52
53
54
55
56
57
58
59
60

Box 1: Social prescribing in the English context

Social prescribing is part of NHS England's commitment, as highlighted in the NHS England Long Term Plan¹³, to make personalised care business as usual across the health and care system. In January 2019, as part of its Universal Personalised Care Plan¹⁴, NHS England announced a major expansion of social prescribing, as one of six components of the comprehensive model of personalised care. NHS England has produced a standard model, the link worker model, of social prescribing in partnership with stakeholders and it has created reference guidance^{15, 16} that provides advice on implementing this link worker model.

To begin to address the gap in the evidence base around social prescriptions, NHS England worked with commissioners, practitioners, providers, evaluators and other stakeholder groups to create a consensus Common Outcomes Framework (COF)¹⁷ on what outcomes and outputs should be measured to demonstrate the impact of social prescribing. Feedback from a wide range of stakeholders (including social prescribing connector schemes, primary care staff, local authorities, local NHS, voluntary community and social enterprises (VCSE) organisations, academics, researchers, public health leaders and other government agencies) was collected to inform the COF. The reference guide encourages the use of SNOMED codes to record social prescribing in patient records as well as the Patient Activation Measure and the ONS Wellbeing Measure to capture outcomes being delivered to patients.

Aim

To measure the uptake and impact of social prescribing and to explore approaches to improve data quality related to social prescribing using the RCGP RSC sentinel network.

Objectives

Our objectives encompass the development of measurement tools, measuring use and impacts as well as feeding back on variation between practices which may be the result of data quality as well as variation in care.

- To identify the characteristics of the individuals who are provided, or decline social prescriptions and the patient and health service outcomes related to their social prescription

- To develop a taxonomy and ontology to capture social prescribing referrals and interventions made in primary care
- To report inter practice variation and to explore opportunities to improve data quality and the quality of social prescribing in primary care.
- To explore the feasibility and willingness of primary care practitioners, including general practitioners and link workers, to routinely collect data (e.g. uptake, service use, health/wellbeing measures) and to use it to evaluate impact of the social prescribing link worker model.

Methods and Analysis

Study design

This mixed methods feasibility study follows the Good Reporting of a Mixed Methods Study (GRAMMS) checklist.¹⁸ The study protocol combines qualitative and quantitative methods and will explore how the RCGP RSC can be used to establish the baseline of existing data, understand outcomes delivered and to explore approaches that can be used to understand and influence how link-worker based models are being implemented in English general practices.

The quantitative methods (WP1) will utilise the RCGP RSC database to test approaches to identify the use and impact of social prescribing.^{11, 12} The qualitative methods (WP2) comprise focus groups and a survey that will be carried out with individuals with experience of primary care. The aim of WP2 is to explore approaches to understand the contextual factors that will have influenced our

1
2
3 quantitative findings with the goal of helping us to identify mechanisms to encourage adoption of
4
5 social prescribing in primary care while improving data quality.
6
7
8
9

10 11 12 Study setting and sample 13

14
15
16
17 For WP1, we will use the sample of over 500 nationally representative GP practices contained within
18
19 the RCGP RSC.^{11,12} For WP2, we will approach and recruit people in person and through existing
20
21 departmental contacts within the University of Oxford and University of Surrey Departments of
22
23 Primary Care. Individuals will be recruited if they have any experience working within primary care
24
25 and are within travelling distance of the University of Oxford or the University of Surrey to attend
26
27 focus groups on our premises.
28
29
30
31
32

33 Data Collection and Data Management 34

35 36 37 38 ***Data collection from volunteer RCGP RSC practices*** 39 40 41 42

43 For this project we propose to use the RCGP RSC sentinel network. The RCGP RSC was established in
44
45 1967 and comprises Computerized Medical Records (CMRs) of pseudonymised data received from
46
47 over 500 primary care practices across England, covering a population of over 4,000,000 currently
48
49 registered patients.^{11, 12}
50
51
52
53

54 RCGP RSC data is registration based, so that every patient is registered with only one practice at a
55
56 time with each patient having a unique patient identifier, the National Health Service (NHS) number.
57
58 The NHS number enables the transition of a patient's medical record to another practice when
59
60

1
2
3 he/she moves to a different location and for the patient's data to link with secondary care and other
4
5 datasets.⁸ Although within this study we will use pseudonymised NHS number throughout
6
7 following RCGP RSC processes.
8
9

10
11
12 CMR data in UK primary care are captured primarily within two Electronic Health Record systems
13
14 which utilise Read and CTV3 codes; both systems, however, will be transitioning to SNOMED CT.
15
16 Read, CTV3 and SNOMED CT codes are used to collate data for primary care including diagnoses,
17
18 processes of care, prescriptions, and results from laboratory-based data.
19
20
21

22
23 We will extract and analyse coded data from primary care practices for five years up to 31 January
24
25 2019. The data extract will include all instances of use of the codes highlighted in Table 1, which
26
27 were derived from the NHS Outcomes Framework for social prescribing.¹⁷
28
29
30
31

32 **Table 1:** NHS Common Outcomes Framework (COF) for Social Prescribing codes. (*NB: codes in italics are not in*
33 *the COF but will be included in the data extract*)
34
35

Readv2	CTV3	SNOMED CT	Term description
9NSE.	9NSE. XaaEA	871691000000100	Social prescribing offered (finding)
8IEp.	8IEp. XaaEB	871711000000103	Social prescribing declined (situation)
8T09.	8T09. XaaEC	871731000000106	Referral to social prescribing service (procedure)
	<i>XagOR</i>	<i>1084281000000109</i>	<i>Signposting to social prescribing service (procedure)</i>

8BAf.	8BAf. XaQvz	515721000000104	<i>Social prescribing for mental health (regime/therapy)</i>
-------	--------------------	-----------------	---

We will also explore other ways of capturing information on the use of social prescribing through the use of a social prescribing ontology. Ontologies are frequently used in health care for modelling the semantics of medical concepts and to facilitate exchange of medical data between different health care service providers.¹⁹ The social prescribing ontology will be underpinned by a taxonomy based on concepts associated with social prescribing practices and the wellbeing of social prescribing recipients. The primary purpose of the taxonomy and ontology is to harmonise data sources containing measures and indicators of social prescribing across various parts of the health system.

The taxonomy will cover several key concepts derived from the five ways to wellbeing model proposed by the New Economics Foundation²⁰ as well as Wilkinson and Marmot's² work on social factors related to health. The concepts will include: social gradient, stress, early life, social exclusion, work/unemployment, social support, addiction, food, transport, ethnic inequalities, health inequalities at older ages, neighbourhood housing and health, sexual behaviours). The ontology will describe these key concepts used within social prescribing. The social prescribing recipient will have one or more characteristics that would qualify them as a social prescribing recipient. In the ontology, these characteristics will be organised according to the biopsychosocial model.²¹ The health care provider will consider these characteristics and decide if a social prescription will be beneficial. The social prescription will enable the social prescribing recipient to access one or more social prescription services. In addition to the services relevant to these concepts, we have also included an additional category, "information/advice service" which includes a range of services that do not fit directly within the scope of original conceptual model of wellbeing or social factors related to health, but have an indirect effect on wellbeing.

1
2
3
4
5 The social prescribing ontology has been implemented according to the web ontology language
6 (OWL) within the Protégé ontology development environment and hosted on the BioPortal ontology
7 repository.²²
8
9
10
11
12
13
14
15
16

17 ***Data collection from focus groups and surveys***

18 *Focus groups*

19
20
21
22
23
24
25
26
27 The focus groups will comprise up to eight participants, as recommended by best practice for this
28 method²³ and will last between 90-120 minutes. The moderator will introduce the discussion topics,
29 monitor the group dynamics to ensure views from all participants are adequately represented and to
30 ensure all discussion topics are covered. A second moderator will take detailed notes of the
31 discussion and help the moderator to keep to time. The focus groups will be recorded and
32 transcribed verbatim.²⁴
33
34
35
36
37
38
39
40
41
42

43 The topics of discussion will include:

- 44 (i) Understanding if and how social prescribing schemes are being utilised by primary care
45 and how social prescribing activity is currently being recorded.
46
47
- 48 (ii) Understanding link worker-based models of social prescribing (including: estimation of
49 investment in social prescribing schemes; estimation of number of link workers; referral
50 process and pathways – e.g. who refers into the scheme; estimation of average amount
51 of time link workers spend with patients; estimation of community groups referred to
52
53
54
55
56
57
58
59
60

- 1
2
3 and numbers of volunteers; nature of community groups referred to; estimation of
4
5 number of personalised support plans co-produced with people receiving support)
6
7
8 (iii) Understanding if there a change in morale of primary care staff
9
10 (iv) Exploring views on the impact of these different models on patients (e.g. through
11
12 measures like the Patient Activation Measure (PAM) and ONS wellbeing measure) and
13
14 primary care (e.g. number of GP appointments, prescriptions for patients, number of
15
16 secondary referrals).
17
18 (v) Exploring approaches that could be used to support primary care to improve data
19
20 quality and recording of data related to social prescribing, including outcome and output
21
22 metrics outlined in the NHS England Social Prescriptions COF.
23
24
25
26
27

28 *Surveys*

29
30
31
32 We will use the findings from the focus groups to develop an online survey to capture the degree of
33
34 consensus with our focus group findings. The surveys will include statements for respondents to
35
36 agree or disagree with. There will also be an opportunity for the respondents to explain why they
37
38 agree or disagree with a statement.
39
40
41
42
43
44
45
46

47 **Data management**

48
49
50
51 Where available, the following output and outcome information derived from the social prescribing
52
53 COF¹⁷ will be analysed for the study:
54
55
56
57

58 **Output metrics**

- characteristics of people referred: age, disability, gender reassignment, marriage or civil partnership, pregnancy and maternity, race, religion or belief, sex, sexual orientation
- referral criteria such as Long Term Conditions or receipt of social care packages

Outcome metrics – Impact on patients and health and care system

- Patient Activation Measures (PAMs)
- ONS wellbeing measures
- GP consultations
- A&E attendance
- Hospital bed days
- Number of medication prescriptions

Data analysis

Statistical and modelling analysis

Descriptive statistics will be used to report the findings and will focus on two key domains:

Social prescription use: Use of social prescribing will be identified using the codes listed in Table 1 as well as through the use of a social prescribing ontology. We will explore the use of both approaches individually and in combination to identify the method that works best.

Social prescription impact: We will explore methods to determine the impact of social prescribing as follows-

- 1
2
3 - Identify individuals who have received a social prescription as well as the details of the social
4 prescription(s) they have received if it is possible to extract this from the existing RCGP RSC
5 data (e.g. frequency, adherence, type of social prescription)
6
7
8
9
10 ○ Where available, identify any clinical conditions of the individuals referred and the
11 clinical condition for which the referral was made (e.g. a walking group to help a
12 person with type 2 diabetes lose weight or a lunch club for an individual
13 experiencing bereavement)
14
15
16
17
18 ○ Where available, identify the characteristics of people referred (see output metrics
19 above)
20
21
22
23 ■ Attempt to identify matched cohorts of patients with similar characteristics
24 but who did not receive a social prescription
25
26
27
28 ● Where available, identify the outcomes (see outcome metrics
29 above) for both cohorts of patients
30
31
32
33
34

35 The goal of these analyses will be to explore if the RCGP RSC can be used to accurately capture the
36 use and impact of social prescribing.
37
38
39
40
41
42
43

44 ***Analysis of focus groups and surveys***

45
46
47
48

49 QSR NVivo 11 and Microsoft Excel will be used to organise and analyse focus group and survey
50 data.²⁵ For the focus group data, we will use Framework Analysis, a well-established approach to
51 observe similarities, discrepancies and interrelationships among the data.²⁶ Framework Analysis
52 consists of a five-step process including:²⁷
53
54
55
56
57
58
59
60

1
2
3 (1) familiarisation: reading the transcripts, reflecting on the research question, and keeping notes of
4
5 potential ideas and recurring concepts.
6
7

8
9
10 (2) identifying a thematic framework: using a priori knowledge of the literature as well as the
11
12 concepts from the first step to create a framework/index to sort the new material into a descriptive
13
14 list of concepts that will be refined to represent the diversity, centrality, and dynamics of
15
16 participants' attitudes.
17

18
19
20
21 (3) indexing: systematically applying the framework to the data, using a numerical system that will
22
23 link them directly to the index. A second analyst will also use the framework to test the transparency
24
25 of the method and compare his/her assumptions with the first analyst's.
26
27

28
29
30 (4) charting: the indexes will be used to create thematic charts, which will include a refined summary
31
32 of major subjects that will have emerged in order to provide a more abstract view of the data.
33
34

35
36
37 (5) mapping and interpretation: interpreting the data as a whole.
38
39

40
41
42
43 For the survey, summary statistics will be used to describe the results based on key themes
44
45 interrogated in the survey. The outputs of the survey will be used to identify opportunities and
46
47 barriers at multiple levels:
48

- 49 - Individual stakeholder level
- 50
- 51 - GP practice level
- 52
- 53 - Regional level
- 54
- 55
- 56
- 57
- 58
- 59
- 60

Patient and public involvement

No patients or public were involved in the development of the research question or design of this study but, where possible, the GP practices we engage with for this study will be asked if they have lay members who would be willing to anonymously comment on the focus group themes.

Project management

The feasibility study will be a collaborative project led by Dr Anant Jani and Professor Simon de Lusignan, with Professor de Lusignan serving as the Principal Investigator. RCGP and NHS England will be collaborators and will oversee the project in collaboration with the principal investigator. The research and information governance framework for RCGP RSC sits within the University of Surrey's formal frameworks for information and research governance. The project team is supported by IT services dedicated to the Faculty and to the Department of Clinical and Experimental Medicine. Our secure analysis servers are optimised for routine healthcare data processing, to provide faster deliveries for our projects.

Ethics and Dissemination

Ethics

For WP1, consent will not be required for these data and we will not process data for people where opt-out codes are present. The data will be pseudonymized and encrypted before uploading to the Clinical Informatics Research Group secure server. Personal data will not be identifiable. This study is

1
2
3 considered to be an “Audit of current practice” when tested against the Health Research Authority
4 (HRA)/Medical Research Council (MRC) “Is my study research” tool and therefore does not require
5
6 specific ethical approval.²⁸ Approval for use of the data was acquired from the RCGP RSC Study
7
8 Approval Committee.
9
10

11
12
13
14 Data extractions will be conducted in accordance with the Clinical Informatics and Health Outcomes
15
16 Research Group’s standard operating procedures for data extraction, pseudonymisation, and
17
18 transfer described previously.²⁹
19
20

21
22
23 Pseudonymisation, the standard approach for protecting patient’s privacy defined by the European
24
25 Data Protection Supervisor (EDPS),³⁰ involves the removal of all personal identifiers from data – such
26
27 as name, date of birth, etc. To minimise the risk of re-identification, all strong identifiers (in this
28
29 study, NHS number) are removed and data is kept encrypted during transfer and is stored on a
30
31 secure network that meets NHS Information Governance standards.³⁰ For this study we need, for
32
33 example, to be able to link outcome and output metrics (see below) associated with the patient
34
35 before and after receiving a social prescription. Pseudonymisation allows us to do this without
36
37 knowing any of the strong personal identifiers of that individual. All data processing and analysis in
38
39 the present proposed study will be conducted within the secure IT environment of the Clinical
40
41 Informatics and Health Outcomes Research Group, at the University of Surrey. The information
42
43 security policies and procedures of the Research Group have been approved by the NHS Digital as
44
45 meeting the Data Security and Privacy (DSP) standards pseudonymising as close to sources as
46
47 possible. If patients have opted out of record sharing, we will not analyse their data.
48
49
50
51
52
53

54
55 For WP2, the University of Surrey Self-Assessment for Governance and Ethics (SAGE) assessment
56
57 was completed.³¹ SAGE indicated that a further ethics and governance application was not
58
59 necessary for our qualitative analyses.
60

Dissemination

The outputs from our research will highlight and capture findings linked to our four objectives, namely:

- An analysis of social prescribing use across the RCGP RSC
- An analysis of the NHS COF social prescribing codes versus the codes from our ontology
- An overview of approaches utilised to determine how the impact of social prescribing could be estimated from different analytical approaches
- An analysis highlighting the findings from our focus groups about different social prescribing models used by practitioners and their willingness to use routine data collection to improve data quality and the outcomes that could be delivered by social prescribing

The outputs from the research will be disseminated primarily through peer review papers in high impact journals within the domains of primary care and health and care systems. We will also present findings at relevant seminars and conferences.

Discussion

Our feasibility study aims to: report baseline levels of social prescription utilisation and the patients within practices who are provided social prescriptions; establish a social prescribing taxonomy/ontology that can capture social prescribing referrals and interventions made in primary care; establish what data can be made available to practices to highlight inter practice variation; to establish what data can be used to enable future evaluation of social prescribing; to explore

1
2
3 approaches to understand the contextual factors that will have influenced our quantitative findings
4 and which can inform the design and development of a more effective taxonomy/ontology for social
5 prescribing; and to ultimately help us understand and encourage adoption of social prescribing in
6 primary care while improving data quality. For the quantitative analyses, we will focus on the
7 specific subgroup of those who are homeless to better understand how they can be identified
8 through the RCGP RSC and to explore whether we can identify the interventions they received and
9 the outcomes delivered to them.
10
11
12
13
14
15
16
17

18
19
20
21 Below we outline several strengths of our study and as well as some limitations which we hope to
22 overcome.
23
24
25
26
27

28 Strengths

29
30
31
32 The key strength of this feasibility study is that it uses an established and nationally representative
33 sentinel network. The practices within the sentinel network are nationally representative and they
34 provide access to a sample of real world evidence (RWE) data. Further to this, the large sample size
35 of this representative dataset and the high-level data completeness of the data are particular
36 strengths of the RCGP RSC dataset.
37
38
39
40
41
42
43
44
45

46 We think that the introduction of a standard methodology for adoption and delivery of social
47 prescribing by GP practices could increase the chances of being able to show benefits. Furthermore,
48 the recording of detailed information on social prescribing (including type, treatment duration, costs
49 and outcomes) is also needed to facilitate the adoption and improvement in the use of social
50 prescriptions. The practical and feasible approaches identified through our project could be
51 adopted by NHS Digital and rolled out nationally across England, yielding information to improve our
52 understanding of the current use and impact of social prescribing and also help to elucidate best
53
54
55
56
57
58
59
60

1
2
3 practice for social prescribing. Furthermore, our findings could also serve as a source of information
4
5 for other countries looking to introduce social prescribing into their health and care systems.
6
7
8
9

10 Limitations

11
12
13
14
15
16 Though nationally representative, because GP practices participate on a voluntary basis, there is
17
18 slight underrepresentation of practices with more deprived patients,³² which means there may be
19
20 some selection bias. Furthermore, identification of patient output and outcome metrics will be
21
22 restricted by primary care clinical codes (i.e. Read, CTV3), which do not always align directly with the
23
24 output and outcome metrics of interest. Finally, because of the limited number of people we can
25
26 recruit for the focus groups and survey, the experiences of the primary care practitioners we recruit
27
28 for WP2 will be limited and may not be able to capture the contextual factors experienced by the
29
30 entire sentinel network.
31
32

33
34
35
36 We will report additional strengths and limitations identified while undertaking the study in the final
37
38 manuscript.
39
40
41
42
43
44

45 **Conclusion**

46
47
48
49
50 This feasibility study will enable us to test approaches to understand the use and impact of social
51
52 prescriptions. Once established, we plan on using our approaches to create a dashboard for GP
53
54 practices to understand their use of social prescriptions in near real time.
55
56
57
58
59
60

1
2
3 **Authors' contributions:** AJ, HL, UH, LM, FF, II and SdL were involved in the design of the study
4
5 protocol; AJ, HL, VTB and SdL were involved in writing and reviewing the manuscript.
6
7

8
9
10 **Funding statement:** This work was supported by funding the Royal College of General Practitioners
11
12 and NHS England.
13
14

15
16 **Competing interests statement:** None of the authors have a competing interest.
17
18
19
20
21
22

23 **References**

- 24
25
26 1. Social prescribing: A pathway to work? [Internet]. The Work Foundation. [cited 2019 April
27
28 12]. Available from: [http://www.theworkfoundation.com/wp-](http://www.theworkfoundation.com/wp-content/uploads/2017/02/412_Social_prescribing.pdf)
29
30 [content/uploads/2017/02/412_Social_prescribing.pdf](http://www.theworkfoundation.com/wp-content/uploads/2017/02/412_Social_prescribing.pdf)
31
32
- 33 2. Social determinants of health: the solid facts. 2nd edition [Internet]. The WHO. [cited 2019
34
35 April 12]. Available from:
36
37 http://www.euro.who.int/_data/assets/pdf_file/0005/98438/e81384.pdf
38
39
- 40 3. Han DS, Bae SS, Kim DH and Choi YJ. Origins and evolution of social medicine and
41
42 contemporary social medicine in Korea. *J Prev Med Public Health*. 2017 05; 50(3): 41-157.
43
44
- 45 4. A discussion document on the concept and principles of health promotion. *Health*
46
47 *Promotion*. 1986 05; 1(1): 73–76.
48
49
- 50 5. Bickerdike L, Booth A, Wilson PM, et al. Social prescribing: less rhetoric and more reality. A
51
52 systematic review of the evidence. *BMJ Open* 2017;7:e013384. doi: 10.1136/bmjopen-2016-
53
54 013384.
55
56
- 57 6. South J, Higgins TJ, Woodall J and White SM. Can social prescribing provide the missing link?
58
59 *Primary Health Care Research & Development* 2008; 9: 310-318.
60

- 1
2
3 7. Social prescribing and community-based support: Summary guide [Internet]. NHS England.
4
5 [cited 2019 April 12]. Available from: [https://www.england.nhs.uk/wp-](https://www.england.nhs.uk/wp-content/uploads/2019/01/social-prescribing-community-based-support-summary-guide.pdf)
6
7 [content/uploads/2019/01/social-prescribing-community-based-support-summary-guide.pdf](https://www.england.nhs.uk/wp-content/uploads/2019/01/social-prescribing-community-based-support-summary-guide.pdf).
8
9
- 10 8. de Lusignan S, van Weel C. The use of routinely collected computer data for research in
11
12 primary care: opportunities and challenges. *Fam Pract*. 2006 Apr;23(2):253-63.
13
- 14 9. de Lusignan S. In this issue: Ontologies a key concept in informatics and key for open
15
16 definitions of cases, exposures, and outcome measures. *J Innov Health Inform*. 2015 Jul
17
18 10;22(2):170. doi: 10.14236/jhi.v22i2.170.
19
- 20 10. Liaw ST, Taggart J, Yu H, de Lusignan S, Kuziemyky C, Hayen A. Integrating electronic health
21
22 record information to support integrated care: practical application of ontologies to improve
23
24 the accuracy of diabetes disease registers. *J Biomed Inform*. 2014 Dec;52:364-72. doi:
25
26 10.1016/j.jbi.2014.07.016.
27
28
- 29 11. de Lusignan S, Correa A, Smith GE, Yonova I, Pebody R, Ferreira F, Elliot AJ, Fleming D. RCGP
30
31 Research and Surveillance Centre: 50 years' surveillance of influenza, infections, and
32
33 respiratory conditions. *Br J Gen Pract*. 2017 Oct;67(663):440-441. doi:
34
35 10.3399/bjgp17X692645.
36
37
- 38 12. Correa A, Hinton W, McGovern A, van Vlymen J, Yonova I, Jones S, de Lusignan S. Royal
39
40 College of General Practitioners Research and Surveillance Centre (RCGP RSC) sentinel
41
42 network: a cohort profile. *BMJ Open*. 2016 Apr 20;6(4):e011092. doi: 10.1136/bmjopen-
43
44 2016-011092.
45
46
- 47 13. NHS Long Term Plan [Internet]. NHS England [cited 2020 Jan 26]. Available from:
48
49 <https://www.longtermplan.nhs.uk/>.
50
51
- 52 14. Delivering universal personalised care [Internet]. NHS England [cited 2020 Jan 26]. Available
53
54 from: <https://www.england.nhs.uk/personalisedcare/upc/>
55
56
- 57 15. Social prescribing link workers [Internet]. NHS England [cited 2020 Jan 26]. Available from:
58
59 <https://www.england.nhs.uk/publication/social-prescribing-link-workers/>
60

16. Social prescribing: applying All Our Health [Internet]. Public Health England [cited 2020 Jan 26]. Available from: <https://www.gov.uk/government/publications/social-prescribing-applying-all-our-health/social-prescribing-applying-all-our-health>
17. Social prescribing and community-based support: Summary guide [Internet]. NHS England [cited 2020 Jan 26]. Available from: <https://www.england.nhs.uk/publication/social-prescribing-and-community-based-support-summary-guide/>
18. O’Cathain A, Murphy E, Nicholl J. The quality of mixed methods studies in health services research. *J Health Serv Res Policy*. 2008 Apr; 13: 92-98.
19. Liyanage H, Krause P, De Lusignan S. Using ontologies to improve semantic interoperability in health data. *J Innov Health Inform*. 2015 Jul 10;22(2):309-15.
20. Aked JO, Marks N, Cordon CO, Thompson S. Five Ways to Wellbeing: A report presented to the Foresight Project on communicating the evidence base for improving people’s wellbeing. London: new economics foundation. 2008.
21. George E, Engel L. The clinical application of the biopsychosocial model. *American journal of Psychiatry*. 1980 May 5;137:535-44.
22. Social prescribing ontology [Internet]. Bioportal [cited 2020 Jan 26]. Available from: <https://bioportal.bioontology.org/ontologies/SOCPRES>
23. Kitzinger J. Qualitative research. Introducing focus groups. *BMJ* 1995;311(7000):299–302.
24. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care*. 2007;19(6):349–57.
25. Zamawe FC. The implication of using NVivo software in qualitative data analysis: evidence-based reflections. *Malawi Med J*. 2015;27(1):13–5.
26. Gale NK, et al. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. *BMC Med Res Methodol*. 2013;13:117.


- 1
2
3 27. Ritchie J, Lewis J. Qualitative research practice: a guide for social science students and
4
5 researchers. London: Sage; 2013.
6
7
8 28. Is my study research? [Internet]. Health Research Authority [cited 2020 Jan 26]. Available
9
10 from: <http://www.hra-decisiontools.org.uk/research/>
11
12 29. de Lusignan S, Borrow R, Tripathy M, et al. Serological surveillance of influenza in an English
13
14 sentinel network: pilot study protocol. BMJ Open 2019;9:e024285. doi:10.1136/bmjopen-
15
16 2018-024285.
17
18 30. de Lusignan S, Metsemakers JF, Houwink P, et al. Routinely collected general practice data:
19
20 goldmines for research? A report of the European Federation for Medical Informatics
21
22 Primary Care Informatics Working Group (EFMI PCIWG) from MIE2006, Maastricht, The
23
24 Netherlands. Inform Prim Care 2006;14:203–9.
25
26
27 31. Welcome to SAGE: Self-Assessment for Governance and Ethics [Internet]. University of
28
29 Surrey [cited 2020 Jan 26]. Available from: <https://surrey.onlinesurveys.ac.uk/sage-1>
30
31
32 32. Correa A, Hinton W, McGovern A, et al. Royal College of General Practitioners Research and
33
34 Surveillance Centre (RCGP RSC) sentinel network: a cohort profile. BMJ Open.
35
36 2016;6(4):e011092.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure Legends**
4

5
6 Figure 1: Upper level design of the social prescribing ontology
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Upper level design of the social prescribing ontology

128x48mm (72 x 72 DPI)

BMJ Open

The use and impact of social prescribing: A mixed methods feasibility study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037681.R1
Article Type:	Protocol
Date Submitted by the Author:	04-May-2020
Complete List of Authors:	Jani, Anant; University of Oxford Medical Sciences Division, Nuffield Department of Primary Care Health Sciences Liyanage, Harshana; University of Oxford Medical Sciences Division, Nuffield Department of Primary Care Health Sciences Hoang, Uy; University of Oxford Medical Sciences Division, Nuffield Department of Primary Care Health Sciences Moore, Lucy; University of Oxford Medical Sciences Division, Nuffield Department of Primary Care Health Sciences Ferreira , Filipa; University of Oxford Medical Sciences Division, Nuffield Department of Primary Care Health Sciences Yonova , Ivelina; Royal College of General Practitioners, Research and Surveillance Centre Tzortziou Brown, Victoria ; Royal College of General Practitioners de Lusignan, Simon; University of Oxford, Nuffield Department of Primary Care Health Sciences; University of Surrey, Department of Clinical and Experimental Medicine
Primary Subject Heading:	General practice / Family practice
Secondary Subject Heading:	Public health, Health informatics, Health services research
Keywords:	GENERAL MEDICINE (see Internal Medicine), Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PREVENTIVE MEDICINE, PRIMARY CARE, SOCIAL MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **The use and impact of social prescribing: A mixed methods feasibility study**
4
5
6 **protocol**
7
8
9

10
11 Anant Jani¹, Harshana Liyanage¹, Uy Hoang¹, Lucy Moore¹, Filipa Ferreira¹, Ivelina Yonova¹,
12
13 Victoria Tzortziou Brown², Simon de Lusignan^{1*}
14
15

- 16
17 1. University of Oxford, Department of Primary Care Radcliffe Primary Care Building,
18 Radcliffe Observatory Quarter, Woodstock Rd, Oxford, Oxfordshire, UK OX2 6GG
19
20 2. Institute of Population Health Sciences, Barts and the London School of Medicine
21 and Dentistry, Queen Mary University of London, E1 2AB, UK
22
23
24
25
26
27

28 ***Correspondences should be addressed to simon.delusignan@phc.ox.ac.uk**
29
30

31
32 **Word count:** 3962
33

34 **Keywords:** social prescribing, health informatics, primary care, social determinants of health
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction

Social prescribing aims to address social determinants of health, which account for 80-90% of health outcomes, but the evidence base behind it is limited due to a lack of data linking social prescribing activity and outcomes.

Methods and analysis

The objective of the quantitative component of this feasibility study is to identify the characteristics of individuals who receive social prescriptions and describe the use and estimate the impact of social prescribing; the latter will be done on a homeless subgroup. We will utilise the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) primary care sentinel network, whose general practices cover a population of over 4,000,000 patients. Social prescribing data will be extracted on all recorded patients for five years up to 31 January 2020.

The objective for the qualitative component of the study is to explore approaches to understand the contextual factors that will have influenced our quantitative findings to identify mechanisms to encourage adoption of social prescribing in primary care while improving data quality. It will comprise up to three 90-120 minute advisory group meetings for six to eight participants.

Participants will be recruited based on their experience of delivering primary care within Oxfordshire and Surrey. The advisory group outputs will be analysed using framework analysis and statements derived from the advisory group meetings will be used to create a survey instrument consisting of statements that surveyees can agree or disagree with.

Ethics and dissemination

1
2
3 All RCGP RSC data are pseudonymised at the point of data extraction. No personally identifiable data
4
5 are required for this investigation. This protocol follows the Good Reporting of a Mixed Methods
6
7 Study (GRAMMS) checklist. The study results will be published in a peer-reviewed journal and the
8
9 dataset will be available to other researchers.
10
11
12
13

14 **Summary: Strengths and limitations of this study**

- 16 - A key strength of this feasibility study is that it uses an established and nationally
17
18 representative sentinel network, The Royal College of General Practitioners Research
19
20 Surveillance Centre (RCGP RSC), which provides access to a large sample of real world
21
22 evidence (RWE) data that has a high-level of data completeness.
23
24
- 25 - The practical and feasible approaches identified through our project could be adopted by
26
27 NHS Digital and rolled out nationally across England, yielding information to improve our
28
29 understanding of the current use and impact of social prescribing and also help to elucidate
30
31 best practice for social prescribing.
32
33
- 34 - A limitation is that though nationally representative, because GP practices participate on a
35
36 voluntary basis, there is slight underrepresentation of practices with more deprived
37
38 patients, which means there may be some selection bias.
39
40
- 41 - Another limitation is that the identification of patient output and outcome metrics will be
42
43 restricted by primary care clinical codes (i.e. Read, CTV3), which do not always align directly
44
45 with the output and outcome metrics of interest.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

It is well established that 80-90% of health outcomes are linked social determinants of health including health-related behaviours, socioeconomic and environmental factors.¹

“Societies that enable all citizens to play a full and useful role in the social, economic and cultural life of their society will be healthier than those where people face insecurity, exclusion and deprivation.”²

Since the 19th century there have been initiatives such as social medicine³ and community health⁴ designed to address these social determinants of health at individual and community levels. There are subtle differences between these initiatives but they all largely focus on needs that remain unaddressed in traditional biomedical models.

Social prescribing is a more recent initiative that has been developed to address social determinants of health. Social prescriptions have been used for several years across European countries. NHS England defines social prescribing as “a way of linking patients in primary care with sources of support within the community to help improve their health and well-being.”⁵ Social prescriptions are varied and include activities focused on health, education, skills development, sports and leisure/art activities. If utilised well, they can help to deliver several benefits to individuals and health and care systems including⁵: giving a route for health and care systems to address social determinants of health; promoting self-care; support job creation by funnelling resources to local Voluntary, Community and Social Enterprise (VCSE) organisations; building stronger communities; reducing service utilisation including GP appointments, secondary care referrals and accident and emergency attendances.

1
2
3 A wide variety of approaches are included within the umbrella of social prescriptions. A 2017
4 systematic review⁶ indicated that while there have been 15 studies into the effects of social
5 prescriptions, none were of sufficient quality to allow a strong recommendation for their use. Since
6 2017, studies using quantitative and qualitative methods have been done to determine the impact
7 of social prescribing but most of these studies have had small sample sizes that may not have been
8 representative of the full breadth of individuals receiving social prescriptions.^{7,8} More robust
9 evidence is required to strategically inform the development of social prescriptions and to establish
10 social prescriptions as an evidence-based intervention that clinicians feel comfortable in regularly
11 using.
12
13

14 A major barrier to the generation of evidence that could facilitate evaluation of social prescribing is
15 the lack of data on what social prescribing activity is taking place and the outcomes delivered for
16 people taking up social prescribing. This stems from the lack of standardisation of recording, a
17 limited list of formal codes associated with social prescribing as well as likely variation in the uptake,
18 use and quality of data recorded by clinicians.
19
20
21
22
23

24 To address these barriers and overcome some of the challenges faced with other studies, we
25 propose a feasibility study utilising a large nationally representative dataset of English general
26 practice to enable us to test approaches to understand the use and impact of social prescriptions.
27 English general practice is an ideal location to assess the feasibility of measuring the uptake and
28 impact of social prescribing. English general practices have a registration-based system (one patient
29 registered with a single practice) and are highly computerised.⁹ Computerised medical record (CMR)
30 systems have been widely used for measuring quality and outcomes in general practice. Where data
31 are likely to be complex, as we anticipate in this study, ontologies provide a formal method to
32 specify how we will measure the uptake and impact of social prescribing.^{10,11}
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

We can readily access a nationally representative sample of data through the Royal College of General Practitioners Research Surveillance Centre (RCGP RSC) sentinel network. The RSC is one of the longest established primary care sentinel networks in Europe, currently consisting of over 1000 general research ready practices and covering a population of over 4,000,000 patients, who are broadly representative of the English population.^{12,13} The RCGP RSC's dataset consists of twice weekly pseudonymised coded extracts of general practice electronic health record data from all major clinical systems.^{12, 13} Finally, England is also an ideal location for this feasibility study because there is a strong national push to promote social prescribing as a mechanism to improve patient and population outcomes while optimising resource utilisation (Box 1).

Box 1: Social prescribing in the English context

Social prescribing is part of NHS England's commitment, as highlighted in the NHS England Long Term Plan¹⁴, to make personalised care business as usual across the health and care system. In January 2019, as part of its Universal Personalised Care Plan¹⁵, NHS England announced a major expansion of social prescribing, as one of six components of the comprehensive model of personalised care. NHS England has produced a standard model, the link worker model, of social prescribing in partnership with stakeholders and it has created reference guidance^{16, 17} that provides advice on implementing this link worker model.

To begin to address the gap in the evidence base around social prescriptions, NHS England worked with commissioners, practitioners, providers, evaluators and other stakeholder groups to create a consensus Common Outcomes Framework (COF)¹⁸ on what outcomes and outputs should be measured to demonstrate the impact of social prescribing. Feedback from a wide range of stakeholders (including social prescribing connector schemes, primary care staff, local authorities, local NHS, voluntary community and social enterprises (VCSE) organisations, academics, researchers, public health leaders and other government agencies) was collected to inform the COF. The reference guide encourages the use of SNOMED codes to record social prescribing in patient records as well as the Patient Activation Measure and the ONS Wellbeing Measure to capture outcomes being delivered to patients.

Aim

This feasibility study will enable us to test approaches to understand the use and impact of social prescriptions.

Objectives

Our objectives encompass the exploration of the development of measurement tools, measuring use and impacts as well as feeding back on variation between practices which may be the result of data quality as well as variation in care.

- To identify the characteristics of the individuals who are provided, or decline social prescriptions and the patient and health service outcomes related to their social prescription, the latter of which will be done on a subgroup of individuals recorded as being homeless
- To develop a taxonomy and ontology to capture social prescribing referrals and interventions made in primary care
- To report inter practice variation and to explore opportunities to improve data quality and the quality of social prescribing in primary care.
- To explore the feasibility and willingness of primary care practitioners, including general practitioners and link workers, to routinely collect data (e.g. uptake, service use, health/wellbeing measures) and to use it to evaluate impact of the social prescribing link worker model.

Methods and Analysis

Study design

1
2
3 This feasibility study will enable us to test approaches to understand the use and impact of social
4 prescriptions. Our study follows the Good Reporting of a Mixed Methods Study (GRAMMS)
5 checklist.¹⁹ The study protocol combines qualitative and quantitative methods and will explore how
6 the RCGP RSC can be used to establish the baseline of existing data, understand outcomes delivered
7 and to explore approaches that can be used to understand and influence how link-worker based
8 models are being implemented in English general practices.
9
10
11
12
13
14
15
16
17

18
19 The quantitative methods (WP1) will utilise the RCGP RSC database to test approaches to identify
20 the use and impact of social prescribing.^{12,13} The qualitative methods (WP2) comprise advisory
21 group meetings that will be carried out with individuals with experience of primary care, which will
22 be used to inform the design of a survey. WP2 will help us explore approaches to understand the
23 contextual factors that will have influenced our quantitative findings with the goal of identifying
24 mechanisms to encourage adoption of social prescribing in primary care while improving data
25 quality.
26
27
28
29
30
31
32
33
34
35
36
37
38

39 Study setting and sample

40
41
42
43
44 For WP1, we will use the sample of over 1000 nationally representative GP practices contained
45 within the RCGP RSC.^{12,13} For WP2, we will approach and recruit people in person and through
46 existing departmental contacts within the University of Oxford and University of Surrey Departments
47 of Primary Care as well as through our contacts within primary care networks in Oxfordshire and
48 Surrey, where members of our study team work. Individuals will be recruited if they have any
49 experience working within primary care (which will include general practitioners, practice nurses,
50 allied health professionals and link workers) and are within travelling distance of the University of
51
52
53
54
55
56
57
58
59
60

1
2
3 Oxford or the University of Surrey to attend advisory group meetings on our premises or via a virtual
4
5 platform if circumstances do not permit face to face meetings (e.g. because of COVID-19).
6
7
8
9

10 Data Collection and Data Management

11 12 13 14 15 ***Data collection from volunteer RCGP RSC practices***

16
17
18
19
20 For this project we propose to use the RCGP RSC sentinel network. The RCGP RSC was established in
21
22 1967 and comprises Computerized Medical Records (CMRs) of pseudonymised data received from
23
24 over 1000 primary care practices across England, covering a population of over 4,000,000 currently
25
26 registered patients.^{12, 13}
27
28
29
30

31 RCGP RSC data is registration based, so that every patient is registered with only one practice at a
32
33 time with each patient having a unique patient identifier, the National Health Service (NHS) number.
34
35 The NHS number enables the transition of a patient's medical record to another practice when
36
37 he/she moves to a different location and for the patient's data to link with secondary care and other
38
39 datasets.⁹ Although within this study we will use pseudonymised NHS number throughout
40
41 following RCGP RSC processes.
42
43
44
45

46
47 CMR data in UK primary care are captured primarily within two Electronic Health Record (EHR)
48
49 systems which utilise Read and CTV3 codes; both systems, however, will be transitioning to SNOMED
50
51 CT. Read, CTV3 and SNOMED CT codes are used to collate data for primary care including diagnoses,
52
53 processes of care, prescriptions, and results from laboratory-based data.
54
55
56
57
58
59
60

We will extract and analyse coded data from primary care practices for five years up to 31 January 2020. The data extract will include all instances of use of the codes highlighted in Table 1, which were derived from the NHS Outcomes Framework for social prescribing.¹⁸

Table 1: NHS Common Outcomes Framework (COF) for Social Prescribing codes. (*NB: codes in italics are not in the COF but will be included in the data extract*)

Readv2	CTV3	SNOMED CT	Term description
9NSE.	9NSE. XaaEA	871691000000100	Social prescribing offered (finding)
8IEp.	8IEp. XaaEB	871711000000103	Social prescribing declined (situation)
8T09.	8T09. XaaEC	871731000000106	Referral to social prescribing service (procedure)
	<i>XagOR</i>	<i>1084281000000109</i>	<i>Signposting to social prescribing service (procedure)</i>
8BAf.	<i>8BAf.</i> <i>XaQvz</i>	<i>515721000000104</i>	<i>Social prescribing for mental health (regime/therapy)</i>

We will also explore other ways of capturing information on the use of social prescribing through the use of a social prescribing ontology. Ontologies are frequently used in health care for modelling the semantics of medical concepts and to facilitate exchange of medical data between different health care service providers.²⁰ The social prescribing ontology will be underpinned by a taxonomy based on concepts associated with social prescribing practices and the wellbeing of social prescribing recipients.

1
2
3 The primary purpose of the taxonomy and ontology is to harmonise data sources containing measures
4 and indicators of social prescribing across various parts of the health system (Figure 1).
5
6
7
8
9

10 The taxonomy will cover several key concepts derived from the five ways to wellbeing model
11 proposed by the New Economics Foundation²¹ as well as Wilkinson and Marmot's² work on social
12 factors related to health. The concepts will include: social gradient, stress, early life, social exclusion,
13 work/unemployment, social support, addiction, food, transport, ethnic inequalities, health
14 inequalities at older ages, neighbourhood housing and health, sexual behaviours). The ontology will
15 describe these key concepts used within social prescribing. The social prescribing recipient will have
16 one of more characteristics that would qualify them as a social prescribing recipient. In the ontology,
17 these characteristics will be organised according to the biopsychosocial model.²² The health care
18 provider will consider these characteristics and decide if a social prescription will be beneficial. The
19 social prescription will enable the social prescribing recipient to access one or more social
20 prescription services. In addition to the services relevant to these concepts, we have also included
21 an additional category, "information/advice service" which includes a range of services that do not
22 fit directly within the scope of original conceptual model of wellbeing or social factors related to
23 health, but have an indirect effect on wellbeing.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 The social prescribing ontology has been implemented according to the web ontology language
44 (OWL) within the Protégé ontology development environment and hosted on the BioPortal ontology
45 repository.²³
46
47
48
49
50
51
52
53
54

55 ***Advisory groups and surveys***

56 *Advisory groups*

57
58
59
60

1
2
3
4
5 The advisory groups will comprise up to eight participants and will adopt methods and best practice
6 normally used for focus groups²⁴ and will last between 90-120 minutes. The moderator will
7 introduce the discussion topics, monitor the group dynamics to ensure views from all participants
8 are adequately represented and to ensure all discussion topics are covered. A second moderator will
9 take detailed notes of the discussion and help the moderator to keep to time. The advisory groups
10 will be recorded and transcribed verbatim.²⁵
11
12
13
14
15
16
17
18
19
20

21 The discussion topics were agreed in consultation with the NHS England personalised care team
22 working on social prescribing. The key topics will include:
23
24

- 25 (i) Understanding if and how social prescribing schemes are being utilised by primary care
26 and how social prescribing activity is currently being recorded.
27
- 28 (ii) Understanding link worker-based models of social prescribing (including: estimation of
29 investment in social prescribing schemes; estimation of number of link workers; referral
30 process and pathways – e.g. who refers into the scheme; estimation of average amount
31 of time link workers spend with patients; estimation of community groups referred to
32 and numbers of volunteers; nature of community groups referred to; estimation of
33 number of personalised support plans co-produced with people receiving support)
34
35 (iii) Understanding if there a change in morale of primary care staff
36
37 (iv) Exploring views on the impact of these different models on patients (e.g. through
38 measures like the Patient Activation Measure (PAM) and ONS wellbeing measure) and
39 primary care (e.g. number of GP appointments, prescriptions for patients, number of
40 secondary referrals).
41
42 (v) Exploring approaches that could be used to support primary care to improve data
43 quality and recording of data related to social prescribing, including outcome and output
44 metrics outlined in the NHS England Social Prescriptions COF.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Surveys

We will use the findings from the advisory groups to develop an online survey to capture the degree of consensus with our advisory group findings. The surveys will include statements for respondents to agree or disagree with. There will also be an opportunity for the respondents to explain why they agree or disagree with a statement.

Data management

Where available, the following output and outcome information derived from the social prescribing COF¹⁸ will be analysed for the study:

Output metrics

- characteristics of people referred: age, disability, gender reassignment, marriage or civil partnership, pregnancy and maternity, race, religion or belief, sex, sexual orientation
- referral criteria such as Long Term Conditions or receipt of social care packages

Outcome metrics – Impact on patients and health and care system

- Patient Activation Measures (PAMs)
- ONS wellbeing measures
- GP consultations
- A&E attendance
- Hospital bed days

- Number of medication prescriptions

Data analysis

Statistical and modelling analysis

Descriptive statistics will be used to report the findings and will focus on two key domains:

Social prescription use: Use of social prescribing will be identified using the codes listed in Table 1 as well as through the use of a social prescribing ontology. We will explore the use of both approaches individually and in combination to identify the method that works best.

Social prescription impact: We will explore methods to determine the impact of social prescribing by focusing on individuals recorded as being homeless:

- We will first identify individuals who have received a social prescription and who are recorded as being homeless. We will then explore methods to determine the details of the social prescription(s) they have received from the existing RCGP RSC data (e.g. frequency, adherence, type of social prescription)
 - Where available, we will attempt identify any additional clinical conditions of the individuals referred
 - Where available, we will attempt to identify the characteristics of people referred (see output metrics above)
 - We will attempt to identify matched cohorts of homeless people with similar characteristics but who did not receive a social prescription

- Where available, identify the outcomes (see outcome metrics above) for both cohorts of homeless people

The goal of these analyses will be to explore if the RCGP RSC can be used to accurately capture the use and impact of social prescribing.

Analysis of advisory groups

QSR NVivo 11 and Microsoft Excel will be used to organise and analyse advisory group meeting outputs.²⁶ We will use Framework Analysis, a well-established approach to observe similarities, discrepancies and interrelationships among the data.²⁷ Framework Analysis consists of a five-step process including:²⁸

(1) familiarisation: reading the transcripts, reflecting on the research question, and keeping notes of potential ideas and recurring concepts.

(2) identifying a thematic framework: using a priori knowledge of the literature as well as the concepts from the first step to create a framework/index to sort the new material into a descriptive list of concepts that will be refined to represent the diversity, centrality, and dynamics of participants' attitudes.

(3) indexing: systematically applying the framework to the data, using a numerical system that will link them directly to the index. A second analyst will also use the framework to test the transparency of the method and compare his/her assumptions with the first analyst's.

1
2
3 (4) charting: the indexes will be used to create thematic charts, which will include a refined summary
4
5 of major subjects that will have emerged in order to provide a more abstract view of the data.
6
7

8
9
10 (5) mapping and interpretation: interpreting the data as a whole.
11
12
13
14
15

16 For the survey, summary statistics will be used to describe the results based on key themes
17
18 interrogated in the survey. The outputs of the survey will be used to identify opportunities and
19
20 barriers at multiple levels:
21

- 22 - Individual stakeholder level
- 23 - GP practice level
- 24 - Regional level
- 25
- 26
- 27
- 28
- 29
- 30
- 31

32 Survey results will be used to inform the survey design for a larger and subsequent study.
33
34
35
36

37 Patient and public involvement

38
39
40

41 No patients or public were involved in the development of the research question or design of this
42
43 study. For the advisory group meetings, the GP practices we engage with for this study will be asked
44
45 to invite patients who would be willing to serve on our advisory group and/or anonymously
46
47 comment on the advisory group themes, as per INVOLVE guidelines.²⁹
48
49
50
51
52
53
54

55 **Project management**

56
57
58
59
60

1
2
3 The feasibility study will be a collaborative project led by Dr Anant Jani and Professor Simon de
4 Lusignan, with Professor de Lusignan serving as the Principal Investigator. RCGP and NHS England
5 will be collaborators and will oversee the project in collaboration with the principal investigator. The
6 research and information governance framework for RCGP RSC sits within the University of Surrey's
7 formal frameworks for information and research governance. The project team is supported by IT
8 services dedicated to the Faculty and to the Department of Clinical and Experimental Medicine. Our
9 secure analysis servers are optimised for routine healthcare data processing, to provide faster
10 deliveries for our projects.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

26 **Ethics and Dissemination**

27 Ethics

28
29
30
31 For WP1, consent will not be required for these data and we will not process data for people where
32 opt-out codes are present, which is currently 2.74%.³⁰ The data will be pseudonymized and
33 encrypted before uploading to the Clinical Informatics Research Group secure server. Personal data
34 will not be identifiable. This study is considered to be an "Audit of current practice" when tested
35 against the Health Research Authority (HRA)/Medical Research Council (MRC) "Is my study
36 research" tool and therefore does not require specific ethical approval.³¹ Approval for use of the
37 data was acquired from the RCGP RSC Study Approval Committee.
38
39
40
41
42
43
44
45
46
47
48
49
50

51 Data extractions will be conducted in accordance with the Clinical Informatics and Health Outcomes
52 Research Group's standard operating procedures for data extraction, pseudonymisation, and
53 transfer described previously.³²
54
55
56
57
58
59
60

1
2
3 Pseudonymisation, the standard approach for protecting patient's privacy defined by the European
4 Data Protection Supervisor (EDPS),³³ involves the removal of all personal identifiers from data – such
5 as name, date of birth, etc. To minimise the risk of re-identification, all strong identifiers (in this
6 study, NHS number) are removed and data is kept encrypted during transfer and is stored on a
7 secure network that meets NHS Information Governance standards.³³ For this study we need, for
8 example, to be able to link outcome and output metrics (see below) associated with the patient
9 before and after receiving a social prescription. Pseudonymisation allows us to do this without
10 knowing any of the strong personal identifiers of that individual. All data processing and analysis in
11 the present proposed study will be conducted within the secure IT environment of the Clinical
12 Informatics and Health Outcomes Research Group, at the University of Surrey. The information
13 security policies and procedures of the Research Group have been approved by the NHS Digital as
14 meeting the Data Security and Privacy (DSP) standards pseudonymising as close to sources as
15 possible. If patients have opted out of record sharing, we will not analyse their data.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 For WP2 where participants in the advisory group meetings are serving as advisors rather than
36 research participants, University of Surrey Self-Assessment for Governance and Ethics (SAGE)³⁴
37 assessment indicated that a further ethics and governance application was not necessary for the
38 analyses linked to this part of the feasibility study.
39
40
41
42
43
44
45

46 Dissemination

47
48
49
50

51 The outputs from our research will highlight and capture findings linked to our four objectives,
52 namely:

- 53 - An analysis of social prescribing use across the RCGP RSC
 - 54 - An analysis of the NHS COF social prescribing codes versus the codes from our ontology
- 55
56
57
58
59
60

- An overview of approaches utilised to determine how the impact of social prescribing could be estimated from different analytical approaches
- An analysis highlighting the findings from our advisory group meetings about different social prescribing models used by practitioners and their willingness to use routine data collection to improve data quality and the outcomes that could be delivered by social prescribing

The outputs from the research will be disseminated primarily through peer reviewed papers in high impact journals within the domains of primary care and health and care systems. We will also present findings at relevant seminars and conferences.

Discussion

Our feasibility study aims to enable us to test approaches to understand the use and impact of social prescriptions. We look to achieve this aim through several objectives including: reporting baseline levels of social prescription utilisation and the patients within practices who are provided social prescriptions; establishing a social prescribing taxonomy/ontology that can capture social prescribing referrals and interventions made in primary care; establishing what data can be made available to practices to highlight inter practice variation; establishing what data can be used to enable future evaluation of social prescribing; exploring approaches to understand the contextual factors that will have influenced our quantitative findings and which can inform the design and development of a more effective taxonomy/ontology for social prescribing; and ultimately helping us understand and encourage adoption of social prescribing in primary care while improving data quality. For the quantitative analyses, we will focus on the specific subgroup of those who are homeless to better understand how they can be identified through the RCGP RSC and to explore whether we can identify the interventions they received and the outcomes delivered to them.

1
2
3
4
5 Below we outline several strengths of our study and as well as some limitations which we hope to
6
7 overcome.
8
9

10 11 12 Strengths 13

14
15
16
17 The key strength of this feasibility study is that it uses an established and nationally representative
18 sentinel network. The practices within the sentinel network are nationally representative and they
19 provide access to a sample of real world evidence (RWE) data to quantify current national use of
20 social prescribing. Further to this, the large sample size of this representative dataset and the high-
21 level data completeness of the data are particular strengths of the RCGP RSC dataset.
22
23
24
25
26
27
28
29

30 We think that the introduction of a standard methodology for adoption and delivery of social
31 prescribing by GP practices could increase the chances of being able to show benefits. Furthermore,
32 the recording of detailed information on social prescribing (including type, treatment duration, costs
33 and outcomes) is also needed to facilitate the adoption and improvement in the use of social
34 prescriptions. The practical and feasible approaches identified through our project could be
35 adopted by NHS Digital and rolled out nationally across England, yielding information to improve our
36 understanding of the current use and impact of social prescribing and also help to elucidate best
37 practice for social prescribing. Furthermore, our findings could also serve as a source of information
38 for other countries looking to introduce social prescribing into their health and care systems.
39
40
41
42
43
44
45
46
47
48
49
50
51

52 53 54 Limitations 55 56 57 58 59 60

1
2
3 Though nationally representative, because GP practices participate on a voluntary basis, there is
4 slight underrepresentation of practices with more deprived patients,¹³ which means there may be
5 some selection bias. Furthermore, identification of patient output and outcome metrics will be
6 restricted by primary care clinical codes (i.e. Read, CTV3), which do not always align directly with the
7 output and outcome metrics of interest. Finally, because of the limited number of people we can
8 recruit for the advisory group meetings and survey, the experiences of the primary care practitioners
9 we recruit for WP2 will be limited and may not be able to capture the contextual factors
10 experienced by the entire sentinel network.
11
12
13
14
15
16
17
18
19
20
21
22

23 We will report additional strengths and limitations identified while undertaking the study in the final
24 manuscript.
25
26
27
28
29
30
31
32

33 **Conclusion**

34
35
36
37 This feasibility study will enable us to test approaches to understand the use and impact of social
38 prescriptions. Once established, we plan on using our approaches to create a dashboard for GP
39 practices to understand their use of social prescriptions in near real time.
40
41
42
43
44
45
46
47

48 **Authors' contributions:** AJ, HL, UH, LM, FF, IY and SdeL were involved in the design of the study
49 protocol; AJ, HL, LM, VTB and SdL were involved in writing and reviewing the manuscript.
50
51
52
53
54

55 **Funding statement:** This work was supported by funding the Royal College of General Practitioners
56 and NHS England.
57
58
59
60

1
2
3 **Acknowledgements:** Practices and patients of the Royal College of General Practitioners Research
4 and Surveillance Centre (RCGP RSC), who allowed their pseudonymised clinical medical records to be
5 used for this study.
6
7

8
9 **Competing interests statement:** None of the authors have a competing interest.
10
11
12
13
14
15

16 **References**

- 17
18 1. Hood CM, Gennuso KP, Swain GR, Catlin BB. County Health Rankings: Relationships Between
19 Determinant Factors and Health Outcomes. *American Journal of Preventive Medicine*. 2016
20 02; 50(2): 129-135.
21
22
- 23 2. Social determinants of health: the solid facts. 2nd edition [Internet]. The WHO. [cited 2019
24 April 12]. Available from:
25 http://www.euro.who.int/_data/assets/pdf_file/0005/98438/e81384.pdf
26
27
- 28 3. Han DS, Bae SS, Kim DH and Choi YJ. Origins and evolution of social medicine and
29 contemporary social medicine in Korea. *J Prev Med Public Health*. 2017 05; 50(3): 41-157.
30
31
- 32 4. A discussion document on the concept and principles of health promotion. *Health*
33 *Promotion*. 1986 05; 1(1): 73–76.
34
35
- 36 5. Social prescribing and community-based support: Summary guide [Internet]. NHS England.
37 [cited 2019 April 12]. Available from: [https://www.england.nhs.uk/wp-](https://www.england.nhs.uk/wp-content/uploads/2019/01/social-prescribing-community-based-support-summary-guide.pdf)
38 [content/uploads/2019/01/social-prescribing-community-based-support-summary-guide.pdf](https://www.england.nhs.uk/wp-content/uploads/2019/01/social-prescribing-community-based-support-summary-guide.pdf).
39
40
- 41 6. Bickerdike L, Booth A, Wilson PM, et al. Social prescribing: less rhetoric and more reality. A
42 systematic review of the evidence. *BMJ Open* 2017;7:e013384. doi: 10.1136/bmjopen-2016-
43 013384.
44
45
- 46 7. Carnes D, Sohanpal R, Frostick C, Hull S, Mathur R, Netuveli G, Tong J, Hutt P, Bertotti M. The
47 impact of a social prescribing service on patients in primary care: a mixed methods
48 evaluation. *BMC Health Services Research* 2017; 17: 835.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 8. [Woodall](#) J, Trigwell J, Bunyan AM, Raine G, Eaton V, Davis J, Hancock L, Cunningham M,
4
5 Wilkinson S. Understanding the effectiveness and mechanisms of a social prescribing service:
6
7 a mixed method analysis. BMC Health Services Research 2018; 18: 604.
8
9
- 10 9. de Lusignan S, van Weel C. The use of routinely collected computer data for research in
11
12 primary care: opportunities and challenges. Fam Pract. 2006 Apr;23(2):253-63.
13
- 14 10. de Lusignan S. In this issue: Ontologies a key concept in informatics and key for open
15
16 definitions of cases, exposures, and outcome measures. J Innov Health Inform. 2015 Jul
17
18 10;22(2):170. doi: 10.14236/jhi.v22i2.170.
19
- 20 21 11. Liaw ST, Taggart J, Yu H, de Lusignan S, Kuziemy C, Hayen A. Integrating electronic health
22
23 record information to support integrated care: practical application of ontologies to improve
24
25 the accuracy of diabetes disease registers. J Biomed Inform. 2014 Dec;52:364-72. doi:
26
27 10.1016/j.jbi.2014.07.016.
28
- 29 30 12. de Lusignan S, Correa A, Smith GE, Yonova I, Pebody R, Ferreira F, Elliot AJ, Fleming D. RCGP
31
32 Research and Surveillance Centre: 50 years' surveillance of influenza, infections, and
33
34 respiratory conditions. Br J Gen Pract. 2017 Oct;67(663):440-441. doi:
35
36 10.3399/bjgp17X692645.
37
- 38 39 13. Correa A, Hinton W, McGovern A, van Vlymen J, Yonova I, Jones S, de Lusignan S. Royal
40
41 College of General Practitioners Research and Surveillance Centre (RCGP RSC) sentinel
42
43 network: a cohort profile. BMJ Open. 2016 Apr 20;6(4):e011092. doi: 10.1136/bmjopen-
44
45 2016-011092.
46
- 47 48 14. NHS Long Term Plan [Internet]. NHS England [cited 2020 Jan 26]. Available from:
49
50 <https://www.longtermplan.nhs.uk/>.
51
- 52 53 15. Delivering universal personalised care [Internet]. NHS England [cited 2020 Jan 26]. Available
54
55 from: <https://www.england.nhs.uk/personalisedcare/upc/>
56
- 57 58 16. Social prescribing link workers [Internet]. NHS England [cited 2020 Jan 26]. Available from:
59
60 <https://www.england.nhs.uk/publication/social-prescribing-link-workers/>


- 1
2
3 17. Social prescribing: applying All Our Health [Internet]. Public Health England [cited 2020 Jan
4
5 26]. Available from: [https://www.gov.uk/government/publications/social-prescribing-](https://www.gov.uk/government/publications/social-prescribing-applying-all-our-health/social-prescribing-applying-all-our-health)
6
7 [applying-all-our-health/social-prescribing-applying-all-our-health](https://www.gov.uk/government/publications/social-prescribing-applying-all-our-health/social-prescribing-applying-all-our-health)
8
9
- 10 18. Social prescribing and community-based support: Summary guide [Internet]. NHS England
11
12 [cited 2020 Jan 26]. Available from: [https://www.england.nhs.uk/publication/social-](https://www.england.nhs.uk/publication/social-prescribing-and-community-based-support-summary-guide/)
13
14 [prescribing-and-community-based-support-summary-guide/](https://www.england.nhs.uk/publication/social-prescribing-and-community-based-support-summary-guide/)
15
16
- 17 19. O’Cathain A, Murphy E, Nicholl J. The quality of mixed methods studies in health services
18
19 research. *J Health Serv Res Policy*. 2008 Apr; 13: 92-98.
- 20
21 20. Liyanage H, Krause P, De Lusignan S. Using ontologies to improve semantic interoperability
22
23 in health data. *J Innov Health Inform*. 2015 Jul 10;22(2):309-15.
- 24
25 21. Aked JO, Marks N, Cordon CO, Thompson S. Five Ways to Wellbeing: A report presented to
26
27 the Foresight Project on communicating the evidence base for improving people’s well-
28
29 being. London: new economics foundation. 2008.
- 30
31 22. George E, Engel L. The clinical application of the biopsychosocial model. *American journal of*
32
33 *Psychiatry*. 1980 May 5;137:535-44.
- 34
35 23. Social prescribing ontology [Internet]. Bioportal [cited 2020 Jan 26]. Available from:
36
37 <https://bioportal.bioontology.org/ontologies/SOCPRES>
38
39
- 40
41 24. Kitzinger J. Qualitative research. Introducing focus groups. *BMJ* 1995;311(7000):299–302.
- 42
43 25. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ):
44
45 a 32-item checklist for interviews and focus groups. *Int J Qual Health Care*. 2007;19(6):349–
46
47 57.
- 48
49 26. Zamawe FC. The implication of using NVivo software in qualitative data analysis: evidence-
50
51 based reflections. *Malawi Med J*. 2015;27(1):13–5.
- 52
53 27. Gale NK, et al. Using the framework method for the analysis of qualitative data in multi-
54
55 disciplinary health research. *BMC Med Res Methodol*. 2013;13:117.
- 56
57
58
59
60

- 1
2
3 28. Ritchie J, Lewis J. Qualitative research practice: a guide for social science students and
4
5 researchers. London: Sage; 2013.
6
7
8 29. INVOLVE: Briefing notes for researchers:public involvement in NHS, public health and social
9
10 care research [Internet]. National Institutes of Health Research [cited 2020 Apr 30]. Available
11
12 from: [https://www.invo.org.uk/wp-](https://www.invo.org.uk/wp-content/uploads/2014/11/9938_INVOLVE_Briefing_Notes_WEB.pdf)
13
14 [content/uploads/2014/11/9938_INVOLVE_Briefing_Notes_WEB.pdf](https://www.invo.org.uk/wp-content/uploads/2014/11/9938_INVOLVE_Briefing_Notes_WEB.pdf)
15
16
17 30. National data opt-out, March 2019 [Internet]. NHS Digital [cited 2020 Apr 30]. Available
18
19 from: [https://digital.nhs.uk/data-and-information/publications/statistical/national-data-opt-](https://digital.nhs.uk/data-and-information/publications/statistical/national-data-opt-out/march-2019/ndop-mar19)
20
21 [out/march-2019/ndop-mar19](https://digital.nhs.uk/data-and-information/publications/statistical/national-data-opt-out/march-2019/ndop-mar19)
22
23
24 31. Is my study research? [Internet]. Health Research Authority [cited 2020 Jan 26]. Available
25
26 from: <http://www.hra-decisiontools.org.uk/research/>
27
28 32. de Lusignan S, Borrow R, Tripathy M, et al. Serological surveillance of influenza in an English
29
30 sentinel network: pilot study protocol. BMJ Open 2019;9:e024285. doi:10.1136/bmjopen-
31
32 2018-024285.
33
34 33. de Lusignan S , Metsemakers JF , Houwink P , et al. Routinely collected general practice data:
35
36 goldmines for research? A report of the European Federation for Medical Informatics
37
38 Primary Care Informatics Working Group (EFMI PCIWG) from MIE2006, Maastricht, The
39
40 Netherlands. Inform Prim Care 2006;14:203–9.
41
42
43 34. Welcome to SAGE: Self-Assessment for Governance and Ethics [Internet]. University of
44
45 Surrey [cited 2020 Jan 26]. Available from: <https://surrey.onlinesurveys.ac.uk/sage-1>
46
47
48
49
50
51
52
53
54

55 Figure Legends

56
57
58 Figure 1: Upper level design of the social prescribing ontology
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Upper level design of the social prescribing ontology

128x48mm (72 x 72 DPI)

BMJ Open

The use and impact of social prescribing: A mixed methods feasibility study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-037681.R2
Article Type:	Protocol
Date Submitted by the Author:	25-Jul-2020
Complete List of Authors:	Jani, Anant; University of Oxford Medical Sciences Division, Nuffield Department of Primary Care Health Sciences Liyanage, Harshana; University of Oxford Medical Sciences Division, Nuffield Department of Primary Care Health Sciences Hoang, Uy; University of Oxford Medical Sciences Division, Nuffield Department of Primary Care Health Sciences Moore, Lucy; University of Oxford Medical Sciences Division, Nuffield Department of Primary Care Health Sciences Ferreira , Filipa; University of Oxford Medical Sciences Division, Nuffield Department of Primary Care Health Sciences Yonova , Ivelina; Royal College of General Practitioners, Research and Surveillance Centre Tzortziou Brown, Victoria ; Royal College of General Practitioners de Lusignan, Simon; University of Oxford, Nuffield Department of Primary Care Health Sciences; University of Surrey, Department of Clinical and Experimental Medicine
Primary Subject Heading:	General practice / Family practice
Secondary Subject Heading:	Public health, Health informatics, Health services research
Keywords:	GENERAL MEDICINE (see Internal Medicine), Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, PREVENTIVE MEDICINE, PRIMARY CARE, SOCIAL MEDICINE

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The use and impact of social prescribing: A mixed methods feasibility study protocol

Anant Jani¹, Harshana Liyanage¹, Uy Hoang¹, Lucy Moore¹, Filipa Ferreira¹, Ivelina Yonova¹,
Victoria Tzortziou Brown^{2,3}, Simon de Lusignan^{1,3*}

1. University of Oxford, Department of Primary Care Radcliffe Primary Care Building, Radcliffe Observatory Quarter, Woodstock Rd, Oxford, Oxfordshire, UK OX2 6GG
2. Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, E1 2AB, UK
3. Royal College of General Practitioners, 30 Euston Square, London, UK

*Correspondences should be addressed to simon.delusignan@phc.ox.ac.uk

Word count: 3962

Keywords: social prescribing, health informatics, primary care, social determinants of health

Abstract

Introduction

Social prescribing aims to address social determinants of health, which account for 80-90% of health outcomes, but the evidence base behind it is limited due to a lack of data linking social prescribing activity and outcomes.

Methods and analysis

The objective of the quantitative component of this feasibility study is to identify the characteristics of individuals who receive social prescriptions and describe the use and estimate the impact of social prescribing; the latter will be done on a homeless subgroup. We will utilise the Oxford Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) primary care sentinel network, whose general practices cover a population of over 4,000,000 patients. Social prescribing data will be extracted on all recorded patients for five years up to 31 January 2020.

The objective for the qualitative component of the study is to explore approaches to understand the contextual factors that will have influenced our quantitative findings to identify mechanisms to encourage adoption of social prescribing in primary care while improving data quality. It will comprise up to three 90-120 minute advisory group meetings for six to eight participants.

Participants will be recruited based on their experience of delivering primary care within Oxfordshire and Surrey. The advisory group outputs will be analysed using framework analysis and will be used to create a survey instrument consisting of statements that surveyees, who will consist of primary care practitioners within the RCGP RSC, can agree or disagree with.

Ethics and dissemination

1
2
3 All RCGP RSC data are pseudonymised at the point of data extraction. No personally identifiable data
4
5 are required for this investigation. This protocol follows the Good Reporting of a Mixed Methods
6
7 Study (GRAMMS) checklist. The study results will be published in a peer-reviewed journal and the
8
9 dataset will be available to other researchers.
10
11
12
13

14 **Summary: Strengths and limitations of this study**

- 16 - A key strength of this feasibility study is that it uses an established and nationally
17
18 representative sentinel network, The Royal College of General Practitioners Research
19
20 Surveillance Centre (RCGP RSC), which provides access to a large sample of real world
21
22 evidence (RWE) data that has a high-level of data completeness.
23
24
- 25 - The practical and feasible approaches identified through our project could be adopted by
26
27 NHS Digital and rolled out nationally across England, yielding information to improve our
28
29 understanding of the current use and impact of social prescribing and also help to elucidate
30
31 best practice for social prescribing.
32
33
- 34 - A limitation is that though nationally representative, because GP practices participate on a
35
36 voluntary basis, there is slight underrepresentation of practices with more deprived
37
38 patients, which means there may be some selection bias.
39
40
- 41 - Another limitation is that the identification of patient output and outcome metrics will be
42
43 restricted by primary care clinical codes (i.e. Read, CTV3), which do not always align directly
44
45 with the output and outcome metrics of interest.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

It is well established that 80-90% of health outcomes are linked social determinants of health including health-related behaviours, socioeconomic and environmental factors.¹:

“Societies that enable all citizens to play a full and useful role in the social, economic and cultural life of their society will be healthier than those where people face insecurity, exclusion and deprivation.”²

Since the 19th century there have been initiatives such as social medicine³ and community health⁴ designed to address these social determinants of health at individual and community levels. There are subtle differences between these initiatives but they all largely focus on needs that remain unaddressed in traditional biomedical models.

Social prescribing is a more recent initiative that has been developed to address social determinants of health. Social prescriptions have been used for several years across European countries. NHS England defines social prescribing as “a way of linking patients in primary care with sources of support within the community to help improve their health and well-being.”⁵ Social prescriptions are varied and include activities focused on health, education, skills development, sports and leisure/art activities. If utilised well, they can help to deliver several benefits to individuals and health and care systems including⁵: giving a route for health and care systems to address social determinants of health; promoting self-care; support job creation by funnelling resources to local Voluntary, Community and Social Enterprise (VCSE) organisations; building stronger communities; reducing service utilisation including GP appointments, secondary care referrals and accident and emergency attendances.

1
2
3 A wide variety of approaches are included within the umbrella of social prescriptions. A 2017
4 systematic review⁶ indicated that while there have been 15 studies into the effects of social
5 prescriptions, none were of sufficient quality to allow a strong recommendation for their use. Since
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A wide variety of approaches are included within the umbrella of social prescriptions. A 2017 systematic review⁶ indicated that while there have been 15 studies into the effects of social prescriptions, none were of sufficient quality to allow a strong recommendation for their use. Since 2017, studies using quantitative and qualitative methods have been done to determine the impact of social prescribing but most of these studies have had small sample sizes that may not have been representative of the full breadth of individuals receiving social prescriptions.^{7,8} More robust evidence is required to strategically inform the development of social prescriptions and to establish social prescriptions as an evidence-based intervention that clinicians feel comfortable in regularly using.

A major barrier to the generation of evidence that could facilitate evaluation of social prescribing is the lack of data on what social prescribing activity is taking place and the outcomes delivered for people taking up social prescribing. This stems from the lack of standardisation of recording, a limited list of formal codes associated with social prescribing as well as likely variation in the uptake, use and quality of data recorded by clinicians.

To address these barriers and overcome some of the challenges faced with other studies, we propose a feasibility study utilising a large nationally representative dataset of English general practice to enable us to test approaches to understand the use and impact of social prescriptions. English general practice is an ideal location to assess the feasibility of measuring the uptake and impact of social prescribing. English general practices have a registration-based system (one patient registered with a single practice) and are highly computerised.⁹ Computerised medical record (CMR) systems have been widely used for measuring quality and outcomes in general practice. Where data are likely to be complex, as we anticipate in this study, ontologies provide a formal method to specify how we will measure the uptake and impact of social prescribing.^{10,11}

1
2
3 We can readily access a nationally representative sample of data through the Oxford Royal College
4 of General Practitioners Research Surveillance Centre (RCGP RSC) sentinel network. The RSC is one
5 of the longest established primary care sentinel networks in Europe, currently consisting of over
6
7 1000 general research ready practices and covering a population of over 4,000,000 patients, who are
8
9 broadly representative of the English population.^{12,13} The RCGP RSC's dataset consists of twice
10
11 weekly pseudonymised coded extracts of general practice electronic health record data from all
12
13 major clinical systems.^{12, 13} Finally, England is also an ideal location for this feasibility study because
14
15 there is a strong national push to promote social prescribing as a mechanism to improve patient and
16
17 population outcomes while optimising resource utilisation (Box 1).
18
19
20
21
22
23
24

Box 1: Social prescribing in the English context

25
26
27 Social prescribing is part of NHS England's commitment, as highlighted in the NHS England Long
28 Term Plan¹⁴, to make personalised care business as usual across the health and care system. In
29 January 2019, as part of its Universal Personalised Care Plan¹⁵, NHS England announced a major
30 expansion of social prescribing, as one of six components of the comprehensive model of
31 personalised care. NHS England has produced a standard model, the link worker model, of
32 social prescribing in partnership with stakeholders and it has created reference guidance^{16, 17}
33 that provides advice on implementing this link worker model.
34
35

36 To begin to address the gap in the evidence base around social prescriptions, NHS England
37 worked with commissioners, practitioners, providers, evaluators and other stakeholder groups
38 to create a consensus Common Outcomes Framework (COF)¹⁸ on what outcomes and outputs
39 should be measured to demonstrate the impact of social prescribing. Feedback from a wide
40 range of stakeholders (including social prescribing connector schemes, primary care staff, local
41 authorities, local NHS, voluntary community and social enterprises (VCSE) organisations,
42 academics, researchers, public health leaders and other government agencies) was collected to
43 inform the COF. The reference guide encourages the use of SNOMED codes to record social
44 prescribing in patient records as well as the Patient Activation Measure and the ONS Wellbeing
45 Measure to capture outcomes being delivered to patients.
46
47
48
49

Aim

50
51
52
53
54
55 This feasibility study will enable us to test approaches to understand the use and impact of social
56
57 prescriptions.
58
59
60

Objectives

Our objectives encompass the exploration of the development of measurement tools, measuring use and impacts as well as feeding back on variation between practices which may be the result of data quality as well as variation in care.

- To identify the characteristics of the individuals who are provided, or decline social prescriptions and the patient and health service outcomes related to their social prescription, the latter of which will be done on a subgroup of individuals recorded as being homeless
- To develop a taxonomy and ontology to capture social prescribing referrals and interventions made in primary care
- To report inter practice variation and to explore opportunities to improve data quality and the quality of social prescribing in primary care.
- To explore the feasibility and willingness of primary care practitioners, including general practitioners and link workers, to routinely collect data (e.g. uptake, service use, health/wellbeing measures) and to use it to evaluate impact of the social prescribing link worker model.

Methods and Analysis

Study design

1
2
3 This feasibility study will enable us to test approaches to understand the use and impact of social
4 prescriptions. Our study follows the Good Reporting of a Mixed Methods Study (GRAMMS)
5 checklist.¹⁹ The study protocol combines qualitative and quantitative methods and will explore how
6 the RCGP RSC can be used to establish the baseline of existing data, understand outcomes delivered
7 and to explore approaches that can be used to understand and influence how link-worker based
8 models are being implemented in English general practices.
9
10
11
12
13
14
15
16
17
18

19 The quantitative methods (WP1) will utilise the RCGP RSC database to test approaches to identify
20 the use and impact of social prescribing.^{12,13} The qualitative methods (WP2) comprise advisory
21 group meetings that will be carried out with individuals with experience of primary care, which will
22 be used to inform the design of a survey that will be disseminated to a wider group of primary care
23 practitioners within the RCGP RSC. WP2 will help us explore approaches to understand the
24 contextual factors that will have influenced our quantitative findings with the goal of identifying
25 mechanisms to encourage adoption of social prescribing in primary care while improving data
26 quality.
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 Study setting and sample

42
43
44
45

46 For WP1, we will use the sample of over 1000 nationally representative GP practices contained
47 within the RCGP RSC.^{12,13} For WP2, we will approach and recruit people in person and through
48 existing departmental contacts within the University of Oxford and University of Surrey Departments
49 of Primary Care as well as through our contacts within primary care networks in Oxfordshire and
50 Surrey, where members of our study team work. Individuals will be recruited if they have any
51 experience working within primary care (which will include general practitioners, practice nurses,
52 allied health professionals and link workers) and are within travelling distance of the University of
53
54
55
56
57
58
59
60

1
2
3 Oxford or the University of Surrey to attend advisory group meetings on our premises or via a virtual
4
5 platform if circumstances do not permit face to face meetings (e.g. because of COVID-19).
6
7
8
9

10 Data Collection and Data Management

11
12
13
14

15 ***Data collection from volunteer RCGP RSC practices***

16
17
18
19

20 For this project we propose to use the RCGP RSC sentinel network. The RCGP RSC was established in
21
22 1967 and comprises Computerized Medical Records (CMRs) of pseudonymised data received from
23
24 over 1000 primary care practices across England, covering a population of over 4,000,000 currently
25
26 registered patients.^{12, 13}
27
28
29
30

31 RCGP RSC data is registration based, so that every patient is registered with only one practice at a
32
33 time with each patient having a unique patient identifier, the National Health Service (NHS) number.
34
35 The NHS number enables the transition of a patient's medical record to another practice when
36
37 he/she moves to a different location and for the patient's data to link with secondary care and other
38
39 datasets.⁹ Although within this study we will use pseudonymised NHS number throughout
40
41 following RCGP RSC processes.
42
43
44
45
46

47 CMR data in UK primary care are captured primarily within two Electronic Health Record (EHR)
48
49 systems which utilise Read and CTV3 codes; both systems, however, will be transitioning to SNOMED
50
51 CT. Read, CTV3 and SNOMED CT codes are used to collate data for primary care including diagnoses,
52
53 processes of care, prescriptions, and results from laboratory-based data.
54
55
56
57
58
59
60

We will extract and analyse coded data from primary care practices for five years up to 31 January 2020. The data extract will include all instances of use of the codes highlighted in Table 1, which were derived from the NHS Outcomes Framework for social prescribing.¹⁸

Table 1: NHS Common Outcomes Framework (COF) for Social Prescribing codes. (*NB: codes in italics are not in the COF but will be included in the data extract*)

Readv2	CTV3	SNOMED CT	Term description
9NSE.	9NSE. XaaEA	871691000000100	Social prescribing offered (finding)
8IEp.	8IEp. XaaEB	871711000000103	Social prescribing declined (situation)
8T09.	8T09. XaaEC	871731000000106	Referral to social prescribing service (procedure)
	<i>XagOR</i>	<i>1084281000000109</i>	<i>Signposting to social prescribing service (procedure)</i>
8BAf.	<i>8BAf.</i> <i>XaQvz</i>	<i>515721000000104</i>	<i>Social prescribing for mental health (regime/therapy)</i>

We will also explore other ways of capturing information on the use of social prescribing through the use of a social prescribing ontology. Ontologies are frequently used in health care for modelling the semantics of medical concepts and to facilitate exchange of medical data between different health care service providers.²⁰ The social prescribing ontology will be underpinned by a taxonomy based on concepts associated with social prescribing practices and the wellbeing of social prescribing recipients.

1
2
3 The primary purpose of the taxonomy and ontology is to harmonise data sources containing measures
4 and indicators of social prescribing across various parts of the health system (Figure 1).
5
6
7
8
9

10 The taxonomy will cover several key concepts derived from the five ways to wellbeing model
11 proposed by the New Economics Foundation²¹ as well as Wilkinson and Marmot's² work on social
12 factors related to health. The concepts will include: social gradient, stress, early life, social exclusion,
13 work/unemployment, social support, addiction, food, transport, ethnic inequalities, health
14 inequalities at older ages, neighbourhood housing and health, sexual behaviours). The ontology will
15 describe these key concepts used within social prescribing. The social prescribing recipient will have
16 one of more characteristics that would qualify them as a social prescribing recipient. In the ontology,
17 these characteristics will be organised according to the biopsychosocial model.²² The health care
18 provider will consider these characteristics and decide if a social prescription will be beneficial. The
19 social prescription will enable the social prescribing recipient to access one or more social
20 prescription services. In addition to the services relevant to these concepts, we have also included
21 an additional category, "information/advice service" which includes a range of services that do not
22 fit directly within the scope of original conceptual model of wellbeing or social factors related to
23 health, but have an indirect effect on wellbeing.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 The social prescribing ontology has been implemented according to the web ontology language
44 (OWL) within the Protégé ontology development environment and hosted on the BioPortal ontology
45 repository.²³
46
47
48
49
50
51
52
53
54

55 ***Advisory groups and surveys***

56 *Advisory groups*

57
58
59
60

1
2
3
4
5 The advisory groups will comprise up to eight participants and will adopt methods and best practice
6 normally used for focus groups²⁴ and will last between 90-120 minutes. The moderator will
7 introduce the discussion topics, monitor the group dynamics to ensure views from all participants
8 are adequately represented and to ensure all discussion topics are covered. A second moderator will
9 take detailed notes of the discussion and help the moderator to keep to time. The advisory groups
10 will be recorded and transcribed verbatim.²⁵
11
12
13
14
15
16
17
18
19
20

21 The discussion topics were agreed in consultation with the NHS England personalised care team
22 working on social prescribing. The key topics will include:
23
24

- 25 (i) Understanding if and how social prescribing schemes are being utilised by primary care
26 and how social prescribing activity is currently being recorded.
27
- 28 (ii) Understanding link worker-based models of social prescribing (including: estimation of
29 investment in social prescribing schemes; estimation of number of link workers; referral
30 process and pathways – e.g. who refers into the scheme; estimation of average amount
31 of time link workers spend with patients; estimation of community groups referred to
32 and numbers of volunteers; nature of community groups referred to; estimation of
33 number of personalised support plans co-produced with people receiving support)
34
35 (iii) Understanding if there a change in morale of primary care staff
36
37 (iv) Exploring views on the impact of these different models on patients (e.g. through
38 measures like the Patient Activation Measure (PAM) and ONS wellbeing measure) and
39 primary care (e.g. number of GP appointments, prescriptions for patients, number of
40 secondary referrals).
41
42 (v) Exploring approaches that could be used to support primary care to improve data
43 quality and recording of data related to social prescribing, including outcome and output
44 metrics outlined in the NHS England Social Prescriptions COF.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Surveys

We will use the findings from the advisory groups to develop an online survey to capture the degree of consensus with our advisory group findings. The surveys will be sent to primary care practitioners within the RCGP RSC and include statements for respondents to agree or disagree with. There will also be an opportunity for the respondents to explain why they agree or disagree with a statement.

Data management

Where available, the following output and outcome information derived from the social prescribing COF¹⁸ will be analysed for the study:

Output metrics

- characteristics of people referred: age, disability, gender reassignment, marriage or civil partnership, pregnancy and maternity, race, religion or belief, sex, sexual orientation
- referral criteria such as Long Term Conditions or receipt of social care packages

Outcome metrics – Impact on patients and health and care system

- Patient Activation Measures (PAMs)
- ONS wellbeing measures
- GP consultations
- A&E attendance
- Hospital bed days

- Number of medication prescriptions

Data analysis

Statistical and modelling analysis

Descriptive statistics will be used to report the findings and will focus on two key domains:

Social prescription use: Use of social prescribing will be identified using the codes listed in Table 1 as well as through the use of a social prescribing ontology. We will explore the use of both approaches individually and in combination to identify the method that works best.

Social prescription impact: We will explore methods to determine the impact of social prescribing by focusing on individuals recorded as being homeless, which is a subgroup that the RCGP RSC team is working with for other projects:

- We will first identify individuals who have received a social prescription and who are recorded as being homeless. We will then explore methods to determine the details of the social prescription(s) they have received from the existing RCGP RSC data (e.g. frequency, adherence, type of social prescription)
 - Where available, we will attempt identify any additional clinical conditions of the individuals referred
 - Where available, we will attempt to identify the characteristics of people referred (see output metrics above)
 - We will attempt to identify matched cohorts of homeless people with similar characteristics but who did not receive a social prescription

- Where available, identify the outcomes (see outcome metrics above) for both cohorts of homeless people

The goal of these analyses will be to explore if the RCGP RSC can be used to accurately capture the use and impact of social prescribing.

Analysis of advisory groups

QSR NVivo 11 and Microsoft Excel will be used to organise and analyse advisory group meeting outputs.²⁶ We will use Framework Analysis, a well-established approach to observe similarities, discrepancies and interrelationships among the data.²⁷ Framework Analysis consists of a five-step process including:²⁸

(1) familiarisation: reading the transcripts, reflecting on the research question, and keeping notes of potential ideas and recurring concepts.

(2) identifying a thematic framework: using a priori knowledge of the literature as well as the concepts from the first step to create a framework/index to sort the new material into a descriptive list of concepts that will be refined to represent the diversity, centrality, and dynamics of participants' attitudes.

(3) indexing: systematically applying the framework to the data, using a numerical system that will link them directly to the index. A second analyst will also use the framework to test the transparency of the method and compare his/her assumptions with the first analyst's.

1
2
3 (4) charting: the indexes will be used to create thematic charts, which will include a refined summary
4
5 of major subjects that will have emerged in order to provide a more abstract view of the data.
6
7

8
9
10 (5) mapping and interpretation: interpreting the data as a whole.
11
12
13

14
15
16 For the survey, summary statistics will be used to describe the results based on key themes
17
18 interrogated in the survey. The outputs of the survey will be used to identify opportunities and
19
20 barriers at multiple levels:
21

- 22 - Individual stakeholder level
- 23 - GP practice level
- 24 - Regional level
- 25
- 26
- 27
- 28
- 29
- 30
- 31

32 Survey results will be used to inform the survey design for a larger and subsequent study.
33
34
35
36

37 Patient and public involvement

38
39
40

41 No patients or public were involved in the development of the research question or design of this
42
43 study. For the advisory group meetings, the GP practices we engage with for this study will be asked
44
45 to invite patients who would be willing to serve on our advisory group and/or anonymously
46
47 comment on the advisory group themes, as per INVOLVE guidelines.²⁹
48
49
50
51
52
53
54

55 **Project management**

56
57
58
59
60

1
2
3 The feasibility study will be a collaborative project led by Dr Anant Jani and Professor Simon de
4 Lusignan, with Professor de Lusignan serving as the Principal Investigator. RCGP and NHS England
5 will be collaborators and will oversee the project in collaboration with the principal investigator. The
6 research and information governance framework for RCGP RSC sits within the University of Surrey's
7 formal frameworks for information and research governance. The project team is supported by IT
8 services dedicated to the Faculty and to the Department of Clinical and Experimental Medicine. Our
9 secure analysis servers are optimised for routine healthcare data processing, to provide faster
10 deliveries for our projects.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

26 **Ethics and Dissemination**

27 Ethics

28
29
30
31 For WP1, consent will not be required for these data and we will not process data for people where
32 opt-out codes are present, which is currently 2.74%.³⁰ The data will be pseudonymized and
33 encrypted before uploading to the Clinical Informatics Research Group secure server. Personal data
34 will not be identifiable. This study is considered to be an "Audit of current practice" when tested
35 against the Health Research Authority (HRA)/Medical Research Council (MRC) "Is my study
36 research" tool and therefore does not require specific ethical approval.³¹ Approval for use of the
37 data was acquired from the RCGP RSC Study Approval Committee.
38
39
40
41
42
43
44
45
46
47
48
49
50

51 Data extractions will be conducted in accordance with the Clinical Informatics and Health Outcomes
52 Research Group's standard operating procedures for data extraction, pseudonymisation, and
53 transfer described previously.³²
54
55
56
57
58
59
60

1
2
3 Pseudonymisation, the standard approach for protecting patient's privacy defined by the European
4 Data Protection Supervisor (EDPS),³³ involves the removal of all personal identifiers from data – such
5 as name, date of birth, etc. To minimise the risk of re-identification, all strong identifiers (in this
6 study, NHS number) are removed and data is kept encrypted during transfer and is stored on a
7 secure network that meets NHS Information Governance standards.³³ For this study we need, for
8 example, to be able to link outcome and output metrics (see below) associated with the patient
9 before and after receiving a social prescription. Pseudonymisation allows us to do this without
10 knowing any of the strong personal identifiers of that individual. All data processing and analysis in
11 the present proposed study will be conducted within the secure IT environment of the Clinical
12 Informatics and Health Outcomes Research Group, at the University of Surrey. The information
13 security policies and procedures of the Research Group have been approved by the NHS Digital as
14 meeting the Data Security and Privacy (DSP) standards pseudonymising as close to sources as
15 possible. If patients have opted out of record sharing, we will not analyse their data.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34

35 For WP2 where participants in the advisory group meetings are serving as advisors rather than
36 research participants, University of Surrey Self-Assessment for Governance and Ethics (SAGE)³⁴
37 assessment indicated that a further ethics and governance application was not necessary for the
38 analyses linked to this part of the feasibility study.
39
40
41
42
43
44
45

46 Dissemination

47
48
49
50

51 The outputs from our research will highlight and capture findings linked to our four objectives,
52 namely:

- 53 - An analysis of social prescribing use across the RCGP RSC
 - 54 - An analysis of the NHS COF social prescribing codes versus the codes from our ontology
- 55
56
57
58
59
60

- An overview of approaches utilised to determine how the impact of social prescribing could be estimated from different analytical approaches
- An analysis highlighting the findings from our advisory group meetings about different social prescribing models used by practitioners and their willingness to use routine data collection to improve data quality and the outcomes that could be delivered by social prescribing

The outputs from the research will be disseminated primarily through peer reviewed papers in high impact journals within the domains of primary care and health and care systems. We will also present findings at relevant seminars and conferences.

Discussion

Our feasibility study aims to enable us to test approaches to understand the use and impact of social prescriptions. We look to achieve this aim through several objectives including: reporting baseline levels of social prescription utilisation and the patients within practices who are provided social prescriptions; establishing a social prescribing taxonomy/ontology that can capture social prescribing referrals and interventions made in primary care; establishing what data can be made available to practices to highlight inter practice variation; establishing what data can be used to enable future evaluation of social prescribing; exploring approaches to understand the contextual factors that will have influenced our quantitative findings and which can inform the design and development of a more effective taxonomy/ontology for social prescribing; and ultimately helping us understand and encourage adoption of social prescribing in primary care while improving data quality. For the quantitative analyses, we will focus on the specific subgroup of those who are homeless to better understand how they can be identified through the RCGP RSC and to explore whether we can identify the interventions they received and the outcomes delivered to them.

1
2
3
4
5 Below we outline several strengths of our study and as well as some limitations which we hope to
6
7 overcome.
8
9

10 11 12 Strengths 13

14
15
16
17 The key strength of this feasibility study is that it uses an established and nationally representative
18 sentinel network. The practices within the sentinel network are nationally representative and they
19 provide access to a sample of real world evidence (RWE) data to quantify current national use of
20 social prescribing. Further to this, the large sample size of this representative dataset and the high-
21 level data completeness of the data are particular strengths of the RCGP RSC dataset.
22
23
24
25
26
27
28
29

30 We think that the introduction of a standard methodology for adoption and delivery of social
31 prescribing by GP practices could increase the chances of being able to show benefits. Furthermore,
32 the recording of detailed information on social prescribing (including type, treatment duration, costs
33 and outcomes) is also needed to facilitate the adoption and improvement in the use of social
34 prescriptions. The practical and feasible approaches identified through our project could be
35 adopted by NHS Digital and rolled out nationally across England, yielding information to improve our
36 understanding of the current use and impact of social prescribing and also help to elucidate best
37 practice for social prescribing. Furthermore, our findings could also serve as a source of information
38 for other countries looking to introduce social prescribing into their health and care systems.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 Limitations 55 56 57 58 59 60

1
2
3 Though nationally representative, because GP practices participate on a voluntary basis, there is
4 slight underrepresentation of practices with more deprived patients,¹³ which means there may be
5 some selection bias. Furthermore, identification of patient output and outcome metrics will be
6 restricted by primary care clinical codes (i.e. Read, CTV3), which do not always align directly with the
7 output and outcome metrics of interest. Finally, because of the limited number of people we can
8 recruit for the advisory group meetings and survey, the experiences of the primary care practitioners
9 we recruit for WP2 will be limited and may not be able to capture the contextual factors
10 experienced by the entire sentinel network.
11
12
13
14
15
16
17
18
19
20
21
22

23 We will report additional strengths and limitations identified while undertaking the study in the final
24 manuscript.
25
26
27
28
29
30
31
32

33 **Conclusion**

34
35
36
37 This feasibility study will enable us to test approaches to understand the use and impact of social
38 prescriptions. Once established, we plan on using our approaches to create a dashboard for GP
39 practices to understand their use of social prescriptions in near real time.
40
41
42
43
44
45
46
47

48 **Authors' contributions:** AJ, HL, UH, LM, FF, IY and SdeL were involved in the design of the study
49 protocol; AJ, HL, LM, VTB and SdeL were involved in writing and reviewing the manuscript.
50
51
52
53
54

55 **Funding statement:** This work was commissioned by the Royal College of General Practitioners and
56 NHS England.
57
58
59
60

1
2
3 **Acknowledgements:** Practices and patients of the Royal College of General Practitioners Research
4 and Surveillance Centre (RCGP RSC), who allowed their pseudonymised clinical medical records to be
5 used for this study.
6
7

8
9 **Competing interests statement:** None of the authors have a competing interest.
10
11
12
13
14
15

16 **References**

- 17
18 1. Hood CM, Gennuso KP, Swain GR, Catlin BB. County Health Rankings: Relationships Between
19 Determinant Factors and Health Outcomes. *American Journal of Preventive Medicine*. 2016
20 02; 50(2): 129-135.
21
22
- 23 2. Social determinants of health: the solid facts. 2nd edition [Internet]. The WHO. [cited 2019
24 April 12]. Available from:
25
26 http://www.euro.who.int/_data/assets/pdf_file/0005/98438/e81384.pdf
27
28
- 29 3. Han DS, Bae SS, Kim DH and Choi YJ. Origins and evolution of social medicine and
30 contemporary social medicine in Korea. *J Prev Med Public Health*. 2017 05; 50(3): 41-157.
31
32
- 33 4. A discussion document on the concept and principles of health promotion. *Health*
34 *Promotion*. 1986 05; 1(1): 73–76.
35
36
- 37 5. Social prescribing and community-based support: Summary guide [Internet]. NHS England.
38 [cited 2019 April 12]. Available from: [https://www.england.nhs.uk/wp-](https://www.england.nhs.uk/wp-content/uploads/2019/01/social-prescribing-community-based-support-summary-guide.pdf)
39 [content/uploads/2019/01/social-prescribing-community-based-support-summary-guide.pdf](https://www.england.nhs.uk/wp-content/uploads/2019/01/social-prescribing-community-based-support-summary-guide.pdf).
40
41
- 42 6. Bickerdike L, Booth A, Wilson PM, et al. Social prescribing: less rhetoric and more reality. A
43 systematic review of the evidence. *BMJ Open* 2017;7:e013384. doi: 10.1136/bmjopen-2016-
44 013384.
45
46
- 47 7. Carnes D, Sohanpal R, Frostick C, Hull S, Mathur R, Netuveli G, Tong J, Hutt P, Bertotti M. The
48 impact of a social prescribing service on patients in primary care: a mixed methods
49 evaluation. *BMC Health Services Research* 2017; 17: 835.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 8. [Woodall](#) J, Trigwell J, Bunyan AM, Raine G, Eaton V, Davis J, Hancock L, Cunningham M,
4
5 Wilkinson S. Understanding the effectiveness and mechanisms of a social prescribing service:
6
7 a mixed method analysis. BMC Health Services Research 2018; 18: 604.
8
9
- 10 9. de Lusignan S, van Weel C. The use of routinely collected computer data for research in
11
12 primary care: opportunities and challenges. Fam Pract. 2006 Apr;23(2):253-63.
13
- 14 10. de Lusignan S. In this issue: Ontologies a key concept in informatics and key for open
15
16 definitions of cases, exposures, and outcome measures. J Innov Health Inform. 2015 Jul
17
18 10;22(2):170. doi: 10.14236/jhi.v22i2.170.
19
- 20 21 11. Liaw ST, Taggart J, Yu H, de Lusignan S, Kuziemyk C, Hayen A. Integrating electronic health
22
23 record information to support integrated care: practical application of ontologies to improve
24
25 the accuracy of diabetes disease registers. J Biomed Inform. 2014 Dec;52:364-72. doi:
26
27 10.1016/j.jbi.2014.07.016.
28
- 29 30 12. de Lusignan S, Correa A, Smith GE, Yonova I, Pebody R, Ferreira F, Elliot AJ, Fleming D. RCGP
31
32 Research and Surveillance Centre: 50 years' surveillance of influenza, infections, and
33
34 respiratory conditions. Br J Gen Pract. 2017 Oct;67(663):440-441. doi:
35
36 10.3399/bjgp17X692645.
37
- 38 39 13. Correa A, Hinton W, McGovern A, van Vlymen J, Yonova I, Jones S, de Lusignan S. Royal
40
41 College of General Practitioners Research and Surveillance Centre (RCGP RSC) sentinel
42
43 network: a cohort profile. BMJ Open. 2016 Apr 20;6(4):e011092. doi: 10.1136/bmjopen-
44
45 2016-011092.
46
- 47 48 14. NHS Long Term Plan [Internet]. NHS England [cited 2020 Jan 26]. Available from:
49
50 <https://www.longtermplan.nhs.uk/>.
51
- 52 53 15. Delivering universal personalised care [Internet]. NHS England [cited 2020 Jan 26]. Available
54
55 from: <https://www.england.nhs.uk/personalisedcare/upc/>
56
- 57 58 16. Social prescribing link workers [Internet]. NHS England [cited 2020 Jan 26]. Available from:
59
60 <https://www.england.nhs.uk/publication/social-prescribing-link-workers/>


- 1
2
3 17. Social prescribing: applying All Our Health [Internet]. Public Health England [cited 2020 Jan
4
5 26]. Available from: [https://www.gov.uk/government/publications/social-prescribing-](https://www.gov.uk/government/publications/social-prescribing-applying-all-our-health/social-prescribing-applying-all-our-health)
6
7 [applying-all-our-health/social-prescribing-applying-all-our-health](https://www.gov.uk/government/publications/social-prescribing-applying-all-our-health/social-prescribing-applying-all-our-health)
8
9
- 10 18. Social prescribing and community-based support: Summary guide [Internet]. NHS England
11
12 [cited 2020 Jan 26]. Available from: [https://www.england.nhs.uk/publication/social-](https://www.england.nhs.uk/publication/social-prescribing-and-community-based-support-summary-guide/)
13
14 [prescribing-and-community-based-support-summary-guide/](https://www.england.nhs.uk/publication/social-prescribing-and-community-based-support-summary-guide/)
15
16
- 17 19. O’Cathain A, Murphy E, Nicholl J. The quality of mixed methods studies in health services
18
19 research. *J Health Serv Res Policy*. 2008 Apr; 13: 92-98.
- 20
21 20. Liyanage H, Krause P, De Lusignan S. Using ontologies to improve semantic interoperability
22
23 in health data. *J Innov Health Inform*. 2015 Jul 10;22(2):309-15.
- 24
25 21. Aked JO, Marks N, Cordon CO, Thompson S. Five Ways to Wellbeing: A report presented to
26
27 the Foresight Project on communicating the evidence base for improving people’s well-
28
29 being. London: new economics foundation. 2008.
- 30
31 22. George E, Engel L. The clinical application of the biopsychosocial model. *American journal of*
32
33 *Psychiatry*. 1980 May 5;137:535-44.
- 34
35 23. Social prescribing ontology [Internet]. Bioportal [cited 2020 Jan 26]. Available from:
36
37 <https://bioportal.bioontology.org/ontologies/SOCPRES>
38
39
- 40
41 24. Kitzinger J. Qualitative research. Introducing focus groups. *BMJ* 1995;311(7000):299–302.
- 42
43 25. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ):
44
45 a 32-item checklist for interviews and focus groups. *Int J Qual Health Care*. 2007;19(6):349–
46
47 57.
- 48
49 26. Zamawe FC. The implication of using NVivo software in qualitative data analysis: evidence-
50
51 based reflections. *Malawi Med J*. 2015;27(1):13–5.
- 52
53 27. Gale NK, et al. Using the framework method for the analysis of qualitative data in multi-
54
55 disciplinary health research. *BMC Med Res Methodol*. 2013;13:117.
- 56
57
58
59
60

- 1
2
3 28. Ritchie J, Lewis J. Qualitative research practice: a guide for social science students and
4
5 researchers. London: Sage; 2013.
6
7
8 29. INVOLVE: Briefing notes for researchers:public involvement in NHS, public health and social
9
10 care research [Internet]. National Institutes of Health Research [cited 2020 Apr 30]. Available
11
12 from: [https://www.invo.org.uk/wp-](https://www.invo.org.uk/wp-content/uploads/2014/11/9938_INVOLVE_Briefing_Notes_WEB.pdf)
13
14 [content/uploads/2014/11/9938_INVOLVE_Briefing_Notes_WEB.pdf](https://www.invo.org.uk/wp-content/uploads/2014/11/9938_INVOLVE_Briefing_Notes_WEB.pdf)
15
16
17 30. National data opt-out, March 2019 [Internet]. NHS Digital [cited 2020 Apr 30]. Available
18
19 from: [https://digital.nhs.uk/data-and-information/publications/statistical/national-data-opt-](https://digital.nhs.uk/data-and-information/publications/statistical/national-data-opt-out/march-2019/ndop-mar19)
20
21 [out/march-2019/ndop-mar19](https://digital.nhs.uk/data-and-information/publications/statistical/national-data-opt-out/march-2019/ndop-mar19)
22
23
24 31. Is my study research? [Internet]. Health Research Authority [cited 2020 Jan 26]. Available
25
26 from: <http://www.hra-decisiontools.org.uk/research/>
27
28 32. de Lusignan S, Borrow R, Tripathy M, et al. Serological surveillance of influenza in an English
29
30 sentinel network: pilot study protocol. BMJ Open 2019;9:e024285. doi:10.1136/bmjopen-
31
32 2018-024285.
33
34 33. de Lusignan S , Metsemakers JF , Houwink P , et al. Routinely collected general practice data:
35
36 goldmines for research? A report of the European Federation for Medical Informatics
37
38 Primary Care Informatics Working Group (EFMI PCIWG) from MIE2006, Maastricht, The
39
40 Netherlands. Inform Prim Care 2006;14:203–9.
41
42
43 34. Welcome to SAGE: Self-Assessment for Governance and Ethics [Internet]. University of
44
45 Surrey [cited 2020 Jan 26]. Available from: <https://surrey.onlinesurveys.ac.uk/sage-1>
46
47
48
49
50
51
52
53
54

55 Figure Legends

56
57
58 Figure 1: Upper level design of the social prescribing ontology
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Upper level design of the social prescribing ontology

128x48mm (72 x 72 DPI)